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There is a constantly increasing number of cancer incidences, however due to improved anti-
cancer therapies, life expectancy is on the rise. More than half of the cancer patients suffer 
from cancer related pain. Thus pain reduces quality of life in growing numbers of patients. 
Cancer pain remains undertreated in almost half of the cancer patients despite the availability 
of effective analgesics. One factor resulting in the under-treatment of cancer pain is poor 
adherence to analgesic regimen. Missed doses may increase intensity of pain and result in 
seeking of emergency medical care, which leads to increased healthcare costs. Inadequate 
adherence to analgesic regimen has been reported in 9-43 % of cancer patients. 
In this study we wanted to determine the rate of adherence to analgesics of cancer outpatients 
who use opioid analgesics in Kuopio University Hospital. Also we aimed to detect probable 
barriers toward pain medications that may contribute to poor adherence. We aimed to 
determine the prevalence of clinically important drug interactions related to analgesics. We 
hoped to determine the frequency of implemented recommendations of pharmacist completed 
medication reviews. We aimed to evaluate the effect of these implemented recommendations 
on patients’ pharmaceutical care issues.  
Data was collected with patient interviews and patients’ medical records. Adherence to 
analgesics was assessed with the Morisky 4-step medication adherence scale (MMAS-4). We 
included 31 patients in this study. Forty-eight percent of the patients strictly adhered to their 
analgesic regimen, while another 48 % moderately adhered to their analgesic regimen. 
Barriers toward pain medications were noticed in the majority of patients. Out of 51 potential 
analgesic interactions 6 were clinically important. 117 recommendations were made to 
physicians considering patients’ medication related problems and 21 were implemented into 
clinical practice. Implemented recommendations were evaluable in 10 patients of whom 7 
benefitted concerning their pharmaceutical care issues and three did receive neither benefit 
nor harm. 
Patients are generally well or moderately adhering to their pain medications. Clinically 
important drug interactions are rare in this population. Physicians were not receptive to the 
recommendations in the medication reviews. Medication reviews may provide benefit for the 
patients’ pharmaceutical care issues. 
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Syövän esiintyvyys kasvaa jatkuvasti ja kehittyneiden syöpähoitojen ansiosta myös 
syöpäpotilaiden elinajanodote pidentyy. Yli puolet syöpää sairastavista kärsii syöpäkivusta, 
joka yhä useammin heikentää potilaiden elämänlaatua. Syöpäkivun alihoidosta kärsii lähes 
puolet syöpäkipua kokevista potilaista, vaikka tehokkaita kipulääkkeitä on saatavilla. Huono 
hoitoon sitoutuminen on yksi tekijä, joka voi johtaa kivun alihoitoon. Kipulääkkeiden 
epäsäännöllinen käyttö voi johtaa kivun voimakkuuden lisääntymiseen. Tämä lisää 
hakeutumista ensiapuun, mikä näkyy terveydenhuollon kustannuksien kasvuna. 
Syöpäpotilaista huonosti kivun hoitoon sitoutuneita on 9-43 % potilaista. 
Tässä tutkimuksessa oli tavoitteena määrittää syöpäpotilaiden kivun hoitoon sitoutumisen aste 
opioideja käyttävillä avopotilailla Kuopion yliopistollisessa sairaalassa. Tavoitteena oli myös 
selvittää mahdolliset kivun hoitoa koskevat ennakkoluulot, jotka voivat heikentää hoitoon 
sitoutumista. Tavoitteena oli määrittää kliinisesti merkittävien kipulääkkeisiin liittyvien 
interaktioiden yleisyys. Tavoitteena oli myös määrittää lääkearvioinneissa tehtyjen 
suositusten toteutumisaste sekä näiden vaikutus potilaiden lääkitysongelmiin. 
Aineisto kerättiin potilashaastatteluilla ja sähköisestä potilastietojärjestelmästä. Hoitoon 
sitoutumista mitattiin 4-portaisella Moriskyn lääkehoitoon sitoutumisen asteikolla (MMAS-
4). Tutkimukseen otettiin 31 potilasta. Tutkimuspotilaista 48 % oli hyvin ja 48 % kohtalaisesti 
kohtalaisesti kivun hoitoon sitoutuneita. Ennakkoluuloja kivun hoitoa kohtaan havaittiin 
suurimmalla osalla potilaista. Tutkimuksessa havaittiin 51 potentiaalista kipulääkkeen 
interaktiota, joista kuusi (6) oli kliinisesti merkittäviä. Lääkearvioinneissa tehtiin lääkäreille 
yhteensä 117 ehdotusta lääkitysongelmiin liittyen, joista 21 toteutettiin. Toteutettujen 
ehdotuksien vaikutusta pystyttiin arvioimaan 10 potilaan kohdalla. Seitsemän potilasta 
hyötyivät tehdyistä muutoksista, mutta kolmen potilaan kohdalla muutoksista ei ollut hyötyä 
eikä haittaa. 
Yleisesti potilaat olivat hyvin tai kohtalaisesti kivun hoitoon sitoutuneita. Kliinisesti 
merkittävät kipulääkkeiden interaktiot ovat harvinaisia tutkimuspopulaatiossa. Lääkärit eivät 
ottaneet lääkearviointien ehdotuksia hyvin huomioon. Lääkearvionneista voi olla hyötyä 
potilaiden lääkitysongelmien vähentämisessä. 
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Definitions and abbreviations 
Medication reconciliation: collecting patient’s most accurate medication history and current 
medications (Medication reconciliation form Appendix 1). 
Medication review: systematic review of the patients medication where Medication safety 
check form was utilized (Appendix 2). 
Medication adherence: describes medication taking behavior whether the patient uses 
prescribed medications according to physicians instructions. 
Pharmaceutical care issues; medication related problems: Problems in pharmacotherapy 
that prevent optimal health outcomes (adverse drug reactions, interactions, dosing problems). 
GFR: Glomerulus filtration rate ml/min. Describes functionality of the kidneys and is 
calculated to each patient according to age, gender, serum creatinine and body weight. 
BPI: Brief pain inventory. A measure which is used to assess cancer pain intensity and its 
disturbance of everyday life. 
Barriers questionnaire: A measure used to assess barriers toward cancer pain medications.  
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1. Introduction 
 
In 2008 global incidence of cancer was 12.7 million and it is estimated to increase 
approximately by 60 % to 20.3 million in year 2030 (Bray et al. 2012). In 2011 the incidence 
of cancer was approximately 30 000 in Finland (Engholm et al. 2013). Cancer related pain is 
very common among oncology patients and more than half of oncology patients experience 
pain (van den Beuken-van Everdingen et al. 2007, Breivik et al. 2009). Even though effective 
medications are available for cancer pain management almost half of the cancer patients 
suffer from undertreated pain (Deandrea et al. 2008). 
Golden standard for cancer pain management is widely used WHO published guideline which 
introduced the three-step pain management ladder for cancer pain (WHO 1996). However, 
cancer pain management is a complex field of medicine because of various and mixed types 
of pain are involved (Vainio & Kalso 2009 pp. 479-484). The basis of cancer pain 
management is around-the-clock and per oral administration using both opioids and non-
opioids and if necessary adjuvant drugs (Kalso 2009 pp. 489-490). Opioids frequently induce 
side effects in patients with cancer pain and thus adverse effects such as constipation have to 
be adequately managed (Palos 2008). 
Analgesic interactions produce a potential risk for a failure in the pain management due to 
high potential for pharmacokinetic or pharmacodynamics interactions (Strouse 2009, 
Overholser & Foster 2011). Respiratory depression is the most serious interactions in opioids 
and benzodiazepines that may result in death (Jann et al. 2014). In addition, opioids used 
concurrently with CNS depressants induce additively sedation (Schumacher et al. 2011 p. 
556) which may induce falls (Lönnroos 2009). Also, NSAIDs may highly increase risk for 
bleeding especially when used together with antithrombotic agents (Delaney et al. 2007). 
One of the reasons for under-treatment of cancer related pain is poor adherence to analgesic 
regimen (Valeberg et al. 2008). There are various factors that affect patient’s medication 
taking behavior for instance fear for side effects and fear for tolerance (Gunnarsdottir et al. 
2002) but factors have not been studied in Finland. Adherence to medication has been 
attempted to be improved with several methods with controversial results but some benefit 
has been seen with educational methods in cancer patients who use analgesics (Oldenmenger 
et al. 2011, Nieuwlaat et al. 2014).  
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Hypothesis for this study was that some patients are poorly adhered to their analgesic 
treatment thus resulting in increased pain which may cause seeking medical aid in emergency 
department. This not only reduces quality of life but also increases health care costs. Aim of 
this study is to determine probable barriers toward analgesic regimen and rate of adherence in 
outpatient oncology clinic to help health care providers to aim resources to overcome 
problems in analgesic adherence. Knowledge of clinically important of analgesic interactions 
in cancer patients helps physicians to pay attention in preventing medication related problems. 
Also this research aimed to discover whether pharmacist conducted medication reviews help 
physicians to detect pharmaceutical care issues and provide benefit to the patient. 
2. Prevalence of cancer pain 
2.2 Cancer pain 
64 % of the patients with advanced or metastatic cancer suffer from cancer pain (van den 
Beuken-van Everdingen et al. 2007). 54 % of the patients undergoing active anti-cancer 
therapy suffer from pain and even 33 % of patients who have undergone curative anti-cancer 
treatment suffer from pain. In a European study on cancer-related pain 72 % of patients 
suffered from pain of whom 93 % considered the pain moderate or severe (Breivik et al. 
2009). The same study showed that 64 % of Finnish cancer patients suffer from pain. Cancer 
related breakthrough pain is prevalent and is present in 59 % of cancer patients (Deandrea et 
al. 2014). 
 
Table 1. Prevalence of pain in different types of cancer in the time of diagnosis (Kalso 2013 
pp. 874).  
Type of cancer Pain as the first 
symptom (%) 
Pain three months 
after diagnosis (%) 
Pain after a year after 
diagnosis (%) 
Lung cancer 44 50 46 
Urinary tract cancer 30 29 30 
GI-tract cancer 23 29 35 
Haematologic cancer 36 27 30 
Skin cancer 11 23 15 
Breast cancer 14 18 32 
Other cancers  20 46 22 
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Pain is frequently found as the first symptom of cancer, see table 1 (Kalso 2013 pp. 874). Pain 
is highly prevalent in the terminal phase of all cancer types and is presented in more specifics 
in table 2. 
Table 2. Pain intensity and prevalence divided by the location of cancer in terminal phase 
(Kalso 2013 pp. 874).  
Location of 
cancer 
Pain intensity 
Mild (%) Moderate (%) Severe (%) Total (%) 
Genitals 10 47 33 90 
Lymphatic and 
blood 
 blood 
29 26 32 87 
Prostata 22 20 41 83 
Head and neck 11 43 29 83 
Large intestine 21 27 32 79 
Breast 25 31 21 78 
Lung 23 30 21 74 
Stomach 30 26 17 74 
Esophagus 21 13 38 71 
Other 27 32 15 73 
All cancers 24 30 21 76 
 
According to Bennett and colleagues, neuropathic pain covers 20 % of the patients with 
cancer related pain but is frequently seen mixed with other types of pain and consequently 
frequency reaches up to 40 % of the patients with cancer pain (Bennett et al. 2012). However, 
Garzón-Rodríguez and colleagues suggest that 33 % of oncology outpatients suffer from 
neuropathic pain (Garzón-Rodríguez et al. 2013). 
2.2 Under-treatment of cancer pain 
Despite high frequency of cancer pain and its well-known reputation, it is still widely 
undertreated (Deandrea et al. 2008). The review conducted by Deandrea et al. showed that 43 
% of the patients with cancer pain are undertreated. Predictors for under-treatment are not 
excessively studied but patients who seem less ill are more likely to be undertreated probably 
due to discrepancy of pain intensity between patient and physician. Meuser and colleagues 
suggested that the most important reason for under-treatment of cancer pain is insufficient 
education of physicians and other health care professionals (Meuser et al. 2001). Poor 
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adherence to analgesic regimen may also result in under-treatment of cancer pain (Valeberg et 
al. 2008). 
3. Mechanisms of cancer pain 
 
Approximately 75 % of cancer pain is caused by disease, 15 % by anti-cancer treatment or 
treatment complications and 10 % by other factors (Kalso 2013 pp. 877). Nociceptive pain is 
the most prevalent type of cancer pain (Vainio & Kalso 2009 pp. 479-484). Other types of 
cancer related pain are neuropathic, immunological and treatment-related pain. It is usually 
possible to determine type of cancer pain for each patient but psychological factors may 
complicate making the diagnosis (Vainio & Kalso 2009 pp. 484). 
3.1 Nociceptive pain 
Nociceptors are nerves that are unmyelinated C-nerve fibers or finely myelinated A-δ fibers 
which detect environmental stimuli, such as pressure (Mantyh et al. 2002). These nerves, 
nociceptors, are located eg. in skin, periosteum, connective tissue and visceral fascia that react 
to a wide range of transmitters that are released due to cancer related mechanical, chemical 
and/or ischemic irritation (Mantyh et al. 2002, Vainio & Kalso 2009 pp. 479-484). Activated 
nociceptor passes the signal on to the central nervous system in the spinal cord which sends 
the signal into the brain where it is sensed as pain (Mantyh et al. 2002). An example of 
mechanic irritation is tumor expansion induced pressure that can activate mechanically gated 
ion channels of the nociceptor which lead into cascade that activates the nociceptor. Cancer 
induced tissue destruction produces inflammation which releases transmitters such as 
prostaglandins and protons which activate the nociceptor. However, tumor consists of many 
other cells than cancer cells such as macrophages, neutrophils and T-cells that excrete 
transmitters such as cytokines that can attach to nociceptors and result in pain. 
Nociceptors are plastic neurons and capable to change their phenotype which may lead to 
sensitization of nociceptors (Mantyh et al. 2002). Sensitization may cause normal stimuli to 
be sensed as pain which is called allodynia or it may cause mild pain to be converted into 
strong pain sensation which is called hyperalgesia. 
3.2 Neuropathic pain 
Neuropathic pain is a result of damage or a disease in the nervous tissue that causes pain 
distinct from nociceptive pain from both its mechanism and management (Kalso 2013 pp. 
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879). Tumor-related pressure or tumor growing inside of the nerve tissue may cause 
permanent neurochemical changes in neurons that cause neuropathic pain (Vainio & Kalso 
2009 pp. 479-484). Common tumor compression locations are spine vertebras, nerve root or 
spinal cord but neuropathic pain may also be caused by interruption with peripheral nerves 
(Kalso 2013 pp. 879). Neuropathic pain may be a result from peripheric nerve sensitization 
that is caused by multiplying of sodium channels in nociceptors (Haanpää 2009 pp. 313). 
Neuropathic pain may also be, at least partially, caused by changes in the central nervous 
system that include for example damage of inhibitory nerve tracks that prevent pain signaling 
to the brain. This is usually a result of excessive nerve stimuli that damage inhibitory neurons 
until cell death resulting in partial absence of inhibitory nerve tracks. In addition, anticancer 
therapies have been noted to cause neuronal damage that induces neuropathic pain (Vainio & 
Kalso 2009 pp. 479-484). In addition, immunological cells attack cancer cells by excreting 
certain type of antigens that may target and also damage nerve cells (Vainio & Kalso 2009 pp. 
479-484). Thus, nerves are suffering from collateral damage by cytokines resulting in 
neuropathic pain. 
3.3 Cancer induced bone pain 
Cancer induced bone pain is a combination of inflammatory, neuropathic, ischemic and 
cancer-specific types of pain (Falk & Dickenson 2014). Inflammatory part is caused by tissue 
damage whereas neuropathic is caused by nerve damage. There is high inter-individual 
variety in intensity of cancer induced bone pain. Some patients suffer from severe pain from 
small metastases whereas patients with multiple larger metastases may feel no pain. This 
indicates that intensity of cancer induced bone pain is dependent on the balance between 
central and peripheral mechanisms. 
4. Management of cancer pain 
 
4.1 WHO guidelines for management of cancer pain 
World health organization (WHO) has published guidelines for the management of cancer 
pain which is translated into 22 different languages (WHO 1996). The first edition was 
published in 1986 and the second in 1996 (São Leão Ferreira et al. 2006). Cancer pain is often 
manageable following the WHO guideline for management of cancer pain (Kalso 2009 pp. 
489-490). Despite effective treatment regimen, pain remains persistent in some cancer 
patients (Breivik et al. 2009). The main endpoints in the WHO guideline are that analgesics 
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are dosed per orally and around-the-clock (Kalso 2009 pp. 489-490). Guideline is very simple 
but it does not fit all patients and drug regimen. Instead, pain management should be selected 
individually for each patient from pain management ladder which is presented in figure 1. 
Guideline has greatly improved cancer pain management since its publication especially in 
the third world countries where availability of cancer treatments and analgesics is limited. The 
primary target in cancer pain management is not achieving full relief from pain but to adjust 
the pain management on a level where the pain is not interfering with everyday life. Also 
chemotherapy is used to treat pain by reducing the size of the tumor (Kalso 2013 pp. 884). 
Radiation is also an effective treatment for cancer pain especially in cancer focuses (Saarto 
2013 pp. 892). 
São Leão Ferreira and colleagues showed in their review article that 46-100% of the patients 
treated according to WHO cancer pain management ladder achieve adequate pain relief (São 
Leão Ferreira et al. 2006). However, Meuser and colleagues showed in their study that 86 % 
of the patients treated for cancer pain according to WHO guideline received adequate pain 
relief (Meuser et al. 2001). Some of the newer studies suggest that WHO guidelines provide 
pain relief for 70 – 80 % of the patients treated according the guidelines (Vargas-Schaffer 
2010). Most patients receive pain relief from applying the WHO pain management guidelines 
but patients also receive difficult side effects from the therapies used (Meuser et al. 2001). 
There has been debate whether the WHO guidelines meet the modern requirements for pain 
management anymore since 10-20 % of the patients with advanced cancer have continuously 
failed to achieve adequate pain relief when treated according to WHO guidelines (Nersesyan 
& Slavin 2007). Deficiencies have been noted to occur especially in treatment of neuropathic 
and bone induced pain. Amendments for the guideline have been suggested concerning acute 
pain, chronic non-cancer pain and pain crisis (Vargas-Schaffer 2010). Nersesyan & Slavin 
proposed a 5-step ladder where the two additional ladders would concern pharmacological 
and surgical management techniques eg. peripheral neurodestruction (Nersesyan & Slavin 
2007). Vargas-Schaffer alternatively suggested that 4-step ladder would provide efficient 
methods to manage cancer pain (Vargas-Schaffer 2010).  
A variety of alternative guidelines have been developed to treat cancer pain (Nersesyan & 
Slavin 2007). For example, two guidelines: National Comprehensive Cancer Network 
(NCCN) clinical practice guidelines in oncology: adult cancer pain and ESMO clinical 
practice guidelines have been developed for management of cancer pain (Ripamonti et al. 
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2012, Swarm et al. 2014). These guidelines provide more versatile perspective into 
management of cancer pain which include for example management of opioid induced side 
effects which is not as detailed in the WHO guidelines (WHO 1996, Ripamonti et al. 2012, 
Swarm et al. 2014). A study conducted by Mearis et al. showed that treatment according to 
NCCN guideline provided some benefit for adult patients compared to standard treatment 
(Mearis et al. 2014) but no such evidence is available for ESMO guidelines. 
4.2 Pain management ladder 
 
The most important aim of the WHO guideline was to achieve adequate pain relief to the most 
of the cancer patients globally (São Leão Ferreira et al. 2006). Pain management ladder is 
designed to be used starting the pain medication regimen from the lowest step, moving 
forward to the next step and add another medication regimen if adequate analgesia is not 
achieved with previous medication (WHO 1996, Kalso 2013 pp. 884). Weak and strong 
opioids should not be combined. An adjuvant drug may be added to the treatment on each 
step either to treat neuropathic pain or to manage drug induced side-effects (Kalso 2013 pp. 
884). Pain management ladder is presented in figure 1. Figure shows recommended doses for 
analgesics but opioid doses are not limited (Kalso 2013 pp. 885). In addition rescue doses 
may be used to patients who suffer from breakthrough pain (WHO 1996). 
4.3 Consumption of pain medications 
 
41 % of the European cancer patients who rate their pain from moderate to severe received 
step III opioids for pain management whereas the percentage in Finland is only 11 % (Breivik 
et al. 2009). However, 89 % of European and 80 % of Finnish cancer patients who suffer from 
moderate to severe pain used some analgesic. In a Japanese study 22.9 % of all cancer 
patients used any analgesic regimen and opioids were used by 9.1 % of all patients (Higashi et 
al. 2012). In Norway the total use of strong opioids has increased by 55 % which is almost 
alone due to increased use of oxycodone and buprenorphine between years 2005 and 2010 
(Neutel et al. 2014). In Finland opioid consumption was in 2013 practically on the same level 
as in 2012 (Finnish statistics on medicine 2013). In 2013 the most used opioid in Finland was 
codeine followed by tramadol and oxycodone. However, mild increase in oxycodone 
consumption was seen between 2011 and 2013 while DDD increased from 1.32 to 1.39. 
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  3rd step: 
Morphine 60-120 mg/d p.o 
Oxycodone 40-90 mg/d p.o. 
Methadone 30-60 mg/d p.o. 
Fentanyl 25-100 µg/d t.d. 
Hydromorphone 6-24 mg/d p.o. 
 2nd step: 
Codein 240 mg/d 
Tramadol 400 mg/d 
Buprenorphine 0.6-1.6 mg/d s.l. 
5-20 µg/h t.d 
 
1st step: 
Ibuprofen ad 3200 mg/d 
Naproxen ad 1000 mg/d 
Diclofenac ad 150 mg/d 
Paracetamol ad 3000 mg/d 
  
An adjuvant analgesic may be added at any point of the treatment:  
amitriptyline, nortriptyline, gabapentin, pregabalin, haloperidol, prednisolone 
Figure 1. WHO ladder for pain management modified by switching drug regimen suggested 
to be used in Finland (modified from WHO 1996, Kalso 2013 pp. 885).  
 
4.4. Paracetamol and NSAIDs 
NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) mediate their effect through prostaglandin 
inhibition which reduces the amount of pain signaling agents in case of inflammatory pain 
(Kalso 2009 pp. 181-182). NSAIDs inhibit COX-1 and COX-2 enzymes which are 
responsible in producing prostaglandins and prostacyclines which are associated in activating 
nerve endings. COX-2 selective NSAIDs bind with higher affinity to COX-2 enzyme which 
aims for inhibition of inflammation without highly affecting to other physiological processes 
such as thrombocyte function. 
Of non-opioid analgesics NSAIDs (non-steroidal anti-inflammatory drugs) are the preferable 
choice for bone metastases and inflammatory cancer related pain (Kalso 2013 pp. 885). 
NSAIDs may be used as a single treatment for mild cancer pain if dosed around-the-clock. An 
opioid should be added to the treatment when pain turns more severe. Combination of an 
opioid and a NSAID seems to have additive analgesic effectbut evidence is not entirely clear 
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(McNicol et al. 2005). NSAIDs have many side effects which of some are severe including 
reducing blood flow in the kidneys and thus NSAIDs should not be combined with 
methotrexate because of synergistic nephrotoxic effect (Kalso 2013 pp. 886). Risk for GI 
bleeding is highly increased when NSAIDs are used regularly which may be managed by 
using PPI-inhibitors, H2-blockers or prostaglandin analog (misoprostole). No sufficient 
evidence has shown superiority of efficacy or safety profile of any NSAID over another 
(McNicol et al. 2005). NSAID induced side effects are discussed in more detail in chapter 
3.7.2. 
Paracetamol 
Mechanism of action of paracetamol is thought to be central but is not entirely known 
(Graham & Scott 2005). However, some of the newer studies have shown that paracetamol 
mediates its antinociceptive effects via weak COX-2 inhibition, indirect cannabinoid 
induction and agonism in central TRPV1 receptors (Ashton 2008, Hinz et al. 2008, Mallet et 
al. 2010). Paracetamol is considered the safest analgesic regimen for treatment of cancer pain 
since it lacks GI-tract targeted side effects compared to NSAIDs (Kalso 2013 pp. 884-885). 
However, there has been discussion of paracetamol’s benefit used concurrently with strong 
opioids and it remains unclear how effective it really is (Axelsson et al. 2008). In Axelsson’s 
et al. study they showed that patients using strong opioids with paracetamol with daily dose > 
2 grams, only 26 % of the patients felt more pain when paracetamol was withdrawn from 
treatment. Controversially, Stockler and colleagues suggested that paracetamol provides pain 
relief and well-being in strong opioid-using patients with persistent pain but their sample size 
was only 34 patients (Stockler et al. 2004).  
However, both paracetamol and NSAIDs may conceal an infection due to their antipyretic 
properties (Anttila 2013 pp. 899). Due to this reason paracetamol is rarely used as a regular 
analgesic in patients with cancer (Kristiina Koskela, verbal information 6.11.2014). 
4.5 Opioids 
Opioids act through opioid receptors both in peripheral and central nervous systems (Davis & 
Pasternak 2009 pp. 7). There exist three types of opioid receptors µ-, κ-, and δ-receptors 
which all have several subtypes (Schumacher et al. 2011 pp. 546). Most of the opioid 
analgesic effect is mediated through binding to opioid receptors in central nervous system. 
The µ-receptors seem to be responsible for most of the analgesic effect, respiratory depression 
and euphoria. However, κ- and δ-receptor are related to these effects yet their part remains 
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partially unclear. Opioids inhibit nerve signaling of pain in the central nervous system thus 
producing analgesic effect.  
Opioids from WHO analgesic ladder step 2 are used to treat mild to moderate pain and strong 
opioids are used to treat moderate to severe pain (Kalso 2013 p. 885-887). Per oral 
administration is preferable since it is safe and almost all patients receive adequate pain relief. 
Morphine is the primary choice for per oral administration of strong opioids in cancer pain yet 
oxycodone is the most used opioid in Finland (Finnish statistics on medicines 2013, Kalso 
2013). If requirement for opioid management stops it is required to unload opioid 
management gradually reducing the dose little by little to avoid withdrawal symptoms (Kalso 
2013 p. 887-888). 
4.5.1 Codeine, tramadol and buprenorfin 
Mildest opioids, codeine and tramadol, are used for mild to moderate cancer pain together 
with paracetamol or ibuprofen (Kalso 2013 pp. 886-887). Codeine is only available as a 
combination product in Finland. Both codeine and tramadol are prodrugs and converted to 
active drugs by CYP 2D6 which contains a mutation in 10 % of Caucasian population making 
these drugs rather problematic to use. Codeine’s analgesic effect is mostly mediated via its 
metabolite morphine (Hardy & Jackson 2009 pp. 81-85). Only 0.6 % of codeine is 
transformed into morphine hence leaving its analgesic effect low. However, some studies 
have challenged this generally approved thought by suggesting that codeine’s analgesic effect 
is not mediated through morphine but through another metabolite C6G (Armstrong & Cozza 
2003, Lötsch et al. 2006). C6G is structurally similar to morphine’s more potent metabolite 
M6G. Since codeine’s analgesic effect on its own is minor it is usually combined with a non-
opioid analgesic (paracetamol, NSAIDs) which seems to have an additive analgesic effect 
(Hardy & Jackson 2009 pp. 81-85). Codeine dosing is not recommended to exceed 65 mg per 
dose because of its side effects rise above benefits thus limiting its use in cancer pain. 
Codeine also has potential for interactions which are considered in chapter 6. Codeine’s side 
effects are as in other opioids constipation, sedation dizziness, nausea, miosis, dry mouth and 
pruritus. 
Tramadol is globally the most used step 2 opioid of WHO analgesic ladder and its efficacy is 
best shown in mild to moderate pain (Davis & Glare 2009 pp. 99-112). Analgesic effect on 
neuropathic pain has been noted in 30-40 % of the patients when tramadol has been used. 
However, tramadol does not compete with stronger opioids in pain relief and rotation is 
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frequently needed within 1-month period after initiating tramadol. Tramadol is a µ-opioid 
receptor agonist yet it has very weak analgesic effect if it is not metabolized into O-
desmethyltramadol (M1) which has much higher affinity to µ-receptors than the parent drug. 
Tramadol is available as a rasemic mixture where (-) -enantiomer inhibits noradrenaline 
reuptake whereas (+) -enantiomer inhibits serotonin reuptake. Therefore tramadol is 
considered to have SNRI-properties which may be at least partially explain its mechanism of 
action in relieving neuropathic pain. However, tramadol and its metabolite block NMDA-
receptors which also may play a role in alleviating neuropathic pain. Most common tramadol 
induced side effects are eg. dizziness, sedation, nausea and orthostatic hypotension. Tramadol 
has the potential to cause serotonin-syndrome, which may present confusion and anxiety, 
especially when used concurrently with other serotonin system affecting drugs (Davis & 
Glare 2009 pp. 99-112, Neuvonen 2012 pp. 1078). Confusion and anxiety are more common 
when tramadol is used in the elderly (Neuvonen 2012 pp. 1078). In addition, tramadol has a 
potential risk to induce convulsions which is a relative contraindication in patients with 
epilepsy (Davis & Glare 2009 pp. 99-112). 
Buprenorphine is a usable choice for mild to moderate pain (Kalso 2013 pp. 887). Its 
analgesic effect is limited when pain turns more severe because of its partial agonist nature. 
However, buprenorphine has been widely used since its transdermal patch was brought on 
market (Davis 2009 pp. 193, 200-201). Buprenorphine is also available as buccal resoriblets 
in Finland (Duodecim-medication database 2015). Buprenorphine causes drowsiness in 30 %, 
constipation and sweating in 27 % and nausea in 24 % of the patients (Davis 2009 pp. 199-
200). As an advantage compared to other opioids buprenorphine can be dosed normally in 
patients with renal impairment and in the elderly (Davis 2009 pp. 200-201, Duodecim-
medication database 2015). 
4.5.2 Morphine 
Morphine is the preferred drug for treatment of moderate to severe cancer pain due to its 
availability, familiarity, effectiveness, simplicity and relatively low cost (Glare 2009 pp. 137-
140). Ceiling dose for morphine is the dose where side effects and benefits are getting off 
balance or side effects increase excessively. However, morphine has been used as high doses 
as 2000 milligrams per day. Clinical use of morphine is usually started by dose titration by 
short acting formula eg. oral solution, administered every four hours and when daily dose is 
defined it is switched to long acting formula (Kalso 2013 pp. 888). Long acting per orally 
administered formulation is the most preferable form of morphine for regular use and it is 
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commonly administered twice a day (Glare 2009 pp. 140). Short acting drugs may be needed 
for breakthrough pain. Morphine can be administered parenterally in patients unable to 
swallow, with strong nausea, GI obstruction or limited absorption from the GI tract. Optimal 
route for parenteral administration is continuous subcutaneous infusion since it requires no 
repeated injections and is thus more pleasant for the patient. Epidural or intra spinal routes of 
administration are used on occasion. 
Excessive side effects cause treatment failure in 10-30 % of the patients using morphine 
(Glare 2009 pp. 132-134). Morphine’s most commonly known side effects are sedation, 
respiratory depression, constipation, and nausea, also presented in table 3. Sedation occurs 
especially in the first few days after initiating morphine treatment but tolerance to sedation is 
usually rapidly built up. In addition, nausea occurs in 30-60 % of opioid-naïve patients but 
tolerance is developed usually within 5-10 days. Morphine has a potential risk to induce 
neurotoxicity syndrome also known as delirium which is potentially life threatening condition 
that requires dose decrease, hydration and treating confusion with haloperidol. It is 
recommended to use morphine with caution in patients with renal impairment (Glare 2009 pp. 
136). 
4.5.3 Oxycodone 
Oxycodone is a strong opioid similar to morphine and is a usable alternative for patients who 
receive intolerant side effects from morphine (Kalso 2013 p. 889). Compared to morphine, 
oxycodone produced similar results in pain relief but is 1.5-fold more potent than morphine 
(Glare & Davis 2009 pp. 162, Wiffen et al. 2013). 
Side effects of oxycodone are similar to other opioids and include confusion, constipation, 
dizziness, dry mouth, nausea and vomiting, pruritus, and somnolence, also presented in table 
3 (Glare & Davis 2009 pp. 160-161). Oxycodone has been shown to induce hallucinations 
less frequently than morphine (Glare & Davis 2009 pp. 161, Wiffen et al. 2013). Also 
morphine induced delirium is frequently resolved when it is switched to oxycodone (Glare & 
Davis 2009 pp. 161). However, oxycodone seems to cause more constipation than morphine 
but less vomiting. Risk for respiratory depression seems to be higher with oxycodone than 
with morphine. 
Hepatic impairment produces a risk for patients using oxycodone since serum levels of 
oxycodone are potentially increased and half-life is prolonged (Glare & Davis 2009 pp. 161-
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162). Oxycodone elimination is also slowed down in patients with renal impairment thus 
caution is recommended when oxycodone is prescribed to patients with renal impairment. 
4.5.4 Methadone 
Methadone is a synthetic opioid that is similar to morphine both in analgesic and side effect 
profiles (Nicholson 2007). However, methadone may produce superior analgesic effect in 
patients who have failed to receive adequate analgesia with morphine (Schumacher et al. 2011 
pp. 557). Methadone has antagonistic effect on NMDA and monoaminergic reuptake 
transporters which may explain at least partially its efficacy in neuropathic pain. 
Elimination of methadone is almost completely dependent on liver metabolism through 
CYP3A4 and CYP2D6 enzymes (Ferrari et al. 2004, Kalso 2013 pp. 890). This produces high 
risk for drug interactions which may cause serious problems in clinical therapy. 
Interindividual variety in the activity of these enzymes produce high variety in bioavailability 
and half-life of methadone and therefore dose titration requires high attention because of risk 
for respiratory depression (Ferrari et al. 2004, Schumacher et al. 2011 pp. 557, Kalso 2013 pp. 
890). 
4.5.5 Fentanyl 
Fentanyl is a synthetic opioid that is approximately 75-100 times more potent than morphine 
(Hall & Hardy 2009 pp. 175). In Finland, Fentanyl is available as transdermal (TD) slow-
release patches, immediate-release buccal tablets, mucosal nasal spray and iv-solution 
(Duodecim-medication database 2015, Kalso 2013 pp. 889-890). Fentanyl patch is a good 
alternative when patient is unable to take per oral medications (Kalso 2013 pp. 889). 
However, it only suits long-term pain management because of delayed analgesic effect. There 
has been shown no significant differences in pain relief between modified release morphine 
and TD fentanyl. However, patients using fentanyl may need more rescue analgesics than 
patients using morphine (Wiffen et al. 2013). Fentanyl has an advantage compared to 
morphine since it does not release histamine, it causes less sedation and constipation 
compared to morphine (Wiffen et al. 2013). 
4.5.6 Hydromorphone 
Hydromorphone is a semi-synthetic derivative of morphine and has similar pharmacological 
profile (Quigley & Glare 2009 pp. 245-250). Hydromorphone has been used as an alternative 
for morphine in opioid rotation but no evidence of its superiority has been discovered. 
Hydromorphone is available as modified and immediate release capsules in Finland and when 
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used regularly it is usually administered twice a day (Duodecim-medication database 2015).  
Hydromorphone’s side effects are as morphine’s except diarrhea has been reported more 
frequently in patients using hydromorphone (Quigley & Glare 2009 pp. 245-250). Compared 
to oxycodone, hydromorphone has shown equivalent pain relief and side effect profile. 
4.6 Breakthrough pain 
Breakthrough cancer pain (BCP) is defined to be sudden or predictable transient worsening of 
pain (Mercadante 2014). Kalso suggests that the dose of opioid used for breakthrough pain is 
1/6 of the daily dose of regularly used opioid (Kalso 2013). Most opioids have been used to 
treat BCP as fast or normal release formulations but mucosal fentanyl has been shown to be 
superior in symptomatic treatment for BCP compared to other opioids in a Cochrane review 
(Zeppetella & Davies 2013). Mucosal products may be administered via nasal or buccal route 
and time of onset derives between 5-15 minutes (Mercadante 2014). In practice it has been 
common to use the same opioid for both long-acting and short-acting purposes eg. controlled-
release morphine as long-acting regimen and normal-release morphine for BCP (Zeppetella & 
Davies 2013). However, studies in the Cochrane review do not show evidence to support this 
practice. Mucosal rapid-onset fentanyl has been used successfully with around-the-clock 
(ATC) morphine, oxycodone, methadone, and hydromorphone.  Increased occurrence of BCP 
may be a sign of inadequate ATC medication thus dose increase of ATC opioid may be 
required to reduce the occurrence of BCP (Mercadante 2014). 
In general BCP is difficult to manage because the required doses to achieve pain relief are 
high which induce more side effects (Mercadante 2014). A large proportion of BCP is caused 
by bone metastases thus movement may induce worsening of pain and avoiding certain 
movements may be the best way to avoid BCP. BCP frequently limits everyday activities and 
highly reduces the quality of life thus its management requires attention. 
4.7 Neuropathic pain 
Neuropathic pain is more complex pain compared to nociceptive pain because when the cause 
of nociceptive pain is treated the pain is usually relieved but in neuropathic pain the pain is 
persistent and may last long after the cause is treated (Fine et al. 2004). Increased incidence of 
neuropathic pain in patients with cancer is partially due to increased use of neuropathy 
inducing chemotherapeutics. This results in a problem where patients have longer life 
expectancy but reduced quality of life. Cancer related neuropathic pain may be a result from a 
variety of different neuropathic syndromes which include eg. phantom pain, post-radiation 
plexopathy, cranial neuropathy and chemotherapy induced neuropathy. Neuropathic pain is a 
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well-known side effect with older chemotherapeutic agents and is most commonly associated 
with cisplatin, oxaliplatin, paclitaxel, docetaxel, vincristine and vinblastine. In some cases 
treatment of the cause of neuropathic pain may bring relief to the patients, eg. corticosteroids 
in management of central nervous system compression (Fallon 2013). 
Management 
Cancer related neuropathic pain is problematic because the available treatments rarely achieve 
full relief from pain (Fallon 2013). However, benefit from gabapentinoids and tricyclic 
antidepressants (TCA) in some neuropathic syndromes has been shown. If the side effects 
from TCA are unmanageable, duloxetine or venlafaxine may be considered as an alternative 
medication for neuropathic cancer pain (Kalso 2013 pp. 890). However, evidence for efficacy 
of duloxetine and venlafaxine is controversial (Fallon 2013, Kalso 2013 pp. 890).  
Gabapentinoids have been established in patients with neuropathic pain and number needed to 
treat (NNT) is 4.2 - 6.4 (Fallon 2013). Gabapentinoids probably mediate their effect by 
blocking calcium channels in the central nervous system. Dizziness and somnolence are the 
most frequent side effects in patients using gabapentinoids. Both pregabalin and gabapentin 
are available as per oral capsules in Finland (Duodecim-medication database 2015). Both 
drugs are eliminated almost entirely through kidneys thus attention and dose alteration in 
patients with renal impairment is suggested (Renbase 2015). 
Tricyclic antidepressants (TCAs) use, including amitriptyline and nortriptyline, is well 
documented in patients with neuropathic pain (Fallon 2013). NNT is 2.1 – 2.8 in various 
neuropathic conditions and it is proposed that TCAs are also effective in cancer-related 
neuropathic pain. TCAs mediate their analgesic effect in neuropathic pain through inhibiting 
serotonin and norepinephrine reuptake in synapses but also by modulating sodium channel 
activity and inhibiting NMDA-receptors (Esin & Yalcin 2014). Patients using tricyclic 
antidepressants frequently suffer from anticholinergic side effects such as constipation, dry 
mouth, urinary retention, orthostatic hypotension, and blurred vision which may lead into 
discontinuation of the therapy. TCAs should be initiated carefully in the elderly and patients 
with cardiac problems. 
A study conducted by Mishra et al. showed some evidence that pregabalin has the most 
efficacy in patients with cancer-related neuropathic pain compared to gabapentin and 
amitriptyline (Mishra et al. 2012). Patients who attended the study needed the least rescue 
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morphine in pregabalin group. However, sample size in the study in overall was 120 and each 
group had only 30 patients. 
4.8 Pain assessment 
It is essential to assess pain to plan pain management strategies and to evaluate achieved 
benefit from the used analgesics to success in the pain management (Burton et al. 2014). 
Large variety of pain measurement tools have been developed and are used for distinct 
purposes in assessment of pain (Breivik et al. 2008). Visual analogue scale (VAS) and 
numerical rating scale (NRS) are well known tools for assessment of intensity of pain. Pain 
interference with sleep, normal activity, social activity, focusing and ability to function is 
suggested to be assessed frequently (Kalso 2013 pp. 882-883). Brief pain inventory (BPI) has 
been developed particularly to assess cancer pain and its interference of normal life in 
association of WHO and Centre for Symptom Evaluation in Cancer Care (Breivik et al. 2008, 
Kumar 2011). It is nowadays used to assess other pain conditions as well. However, BPI is 
the most used measurement tool to assess cancer pain (Breivik et al. 2008). 
Visual analogue scale (VAS), numerical rating scale (NRS) and verbal rating scale (VRS) are 
frequently used to assess pain intensity (Jensen 2003). VAS and NRS have shown almost 
identical results in pain assessment (Breivik et al. 2008). However, VAS has higher failure 
rate especially in the elderly and patients who use opioids because it is harder to understand 
and to complete compared to the other two (Jensen 2003). NRS and VAS seem equally 
sensitive in assessing pain intensity. Patients frequently prefer NRS over VAS because it is 
easier to use. Visual analogue scale (VAS) is usually a 100 mm horizontal line on which 
patient makes a mark to point intensity of pain (Breivik et al. 2008). NRS is usually a 
numerical scale from 0 to 10 which of patient chooses the most fitting number to describe 
intensity of pain (Jensen 2003). Verbal rating scale usually consists of four items which 
describe intensity of pain: none, some, moderate and severe. VAS cut-off points have been 
suggested to be < 3.5 cm for mild pain, 3.5 – 6.4 cm to implicate moderate pain, and 6.5 – 10 
cm for severe pain (Boonstra et al. 2014). Adequate level for successful pain management is 
considered to be VAS or NRS score 3 or less (Kalso 2013 pp. 887). 
BPI assesses chronic pain intensity, its interference with normal life and received relief from 
the pain management by numerical scale from 0 to 10 and is usually completed in 2-3 minutes 
(Breivik et al. 2008, Kumar 2011). Evidence for BPI’s validity and reliability has been shown 
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as an assessment tool to evaluate pain in patients with cancer in several languages (Kumar 
2011). 
5. Challenges in cancer pain management 
 
5.1 Cancer-induced bone pain 
Cancer-induced bone pain (CIBP) consists of background pain, breakthrough pain at rest and 
breakthrough pain at movement (Colvin & Fallon 2008). Bone metastase -related pain may be 
treated with analgesics, radiation, radionucleotides and bisfosfonates which have been shown 
to reduce the occurrence of breakthrough pain (Mercadante 2014). Radiotherapy is the most 
effective way to treat CIBP yet frequently other treatment options are required for adequate 
pain relief (Colvin & Fallon 2008, Saarto 2013 pp. 892). Opioids are very useful for 
symptomatic treatment of CIBP both in background pain and in breakthrough pain, however 
breakthrough pain is more difficult to manage (Colvin & Fallon 2008). Only small proportion 
of patients can predict pain in movement and manage it with medications. Devices to support 
bone tissue are available to avoid fractures of bone metastase induced fragility of the bone 
(Mercadante 2014). 
Opioids remain the basis in the pain relief of bone-induced pain and suitable opioid is 
required to be discovered to each patient individually (Colvin & Fallon 2008). There is a 
demand for a long acting opioid to treat the background pain and a rapid onset opioid to 
manage breakthrough pain. According to Colvin & Fallon there is limited evidence to support 
NSAID use in CIBP but Kalso suggests that NSAIDs are usually effective in patients with 
CIBP and should be continued when opioid is added (Colvin & Fallon 2008, Kalso 2013 pp. 
885). Nevertheless, in practice NSAIDs are frequently used for CIBP despite the controversial 
evidence of their efficacy (Colvin & Fallon 2008). 
There is some evidence to support that some bisphosphonates may provide pain relief but the 
effect is not immediate (Wong & Wiffen 2002, Wong et al. 2012). The mechanism of 
bisphosphonate induced analgesia remains unknown but reduced acidosis, growth factor 
release and peripheral neural sensitization are suggested to be involved (Gralow & Tripathy 
2007). It is yet undetermined whether bisphosphonates are cost-effective in management of 
CIBP but Gralow and Tripathy suggest that they show potential as co-analgesics. 
Bisphosphonates may induce renal toxicity, GI-toxicity and more rarely osteonecrosis of the 
jaw. 
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5.2 Side effects  
Side effects of the analgesic regimen used in cancer pain management are of great importance 
in patient adherence to pain medication (Palos 2008). In pain management it is an important 
task for the physician to balance between the received benefit and the risk for side effects of 
the pain medications. 
Opioids 
The most common side effects with short term use of opioids are constipation, sedation, sleep 
disorders, nausea and vomiting, pruritus, respiratory depression, and urinary retention (Palos 
2008). Constipation and sedation occur in 27-70 % and 20-70 % of the patients, respectively, 
whereas dry mouth is the most common opioid induced side effect (Palos 2008, Glare 2009 
pp. 132). Opioid induced side effects, especially delirium, occur more commonly in the 
elderly (Tilvis et al. 2011 pp. 126). Side effects of opioids are presented in table 3. According 
to Palos, long-term side effects of opioids are not well-known thus warrant for further studies 
(Palos 2008). 
Table 3. General opioid induced side effects (after Palos 2008, Glare 2009 pp. 132). 
Common  Occasional Rare 
Nausea and vomiting Dry mouth Respiratory depression 
Sedation Sweating Psychological dependance 
Unsteadiness/hypotension Pruritus  
Delirium Hallucinations  
Constipation Myoclonus  
 Urinary retention  
 
Opioid induced respiratory depression is dose dependent and tolerance for respiratory 
depression is developed quickly (Davis 2009 pp. 354-355). However, in case of respiratory 
depression opioid should be discontinued and naloxone should be given if breathing 
frequency is less than 8 / min until frequency increases ad 10 / min. Respiratory depression 
may result in death if required attention is not given. 
According to Kalso and colleagues 41 % of the patients taking oral opioids for non-cancer 
pain suffer from opioid induced constipation whereas some studies vary between 27-70 % 
(Kalso et al. 2004, Palos 2008, Davis 2009 pp. 357). In addition to opioids, constipation is a 
result from multiple factors in cancer patients eg. fluid intake and anticancer drugs (Davis 
26 
 
2009 pp. 357). No tolerance is developed for constipation thus it is persistent side effect as 
long as opioid is used (Kalso 2013). Opioid induced constipation is suggested to be treated 
with laxatives such as lactulose, macrogols or sodium picosulfate or in cases where laxatives 
are not enough with parenteral methylnaltrexone (Davis 2009 pp. 357, Kalso 2009 pp. 195-
196). 
Sedation is very common side effect in patients using opioids especially after initiation of the 
therapy or a dose increase (Davis 2009 pp. 355). However, tolerance is built up to sedation 
quickly but if sedation is persistent it may be a result from concomitant use of other CNS 
affecting drugs or comorbidities. Thus, management of persistent sedation starts with 
mapping of comorbidities and other sedative medications. 
Nausea and vomiting are experienced by 15-30 % of the patients using opioids (Davis 2009 
pp. 357). Usually nausea is withdrawn within few days after initiating the treatment yet more 
persistent nausea and vomiting have been successfully treated with neuroleptics such as 
haloperidol (Kalso 2013). Nausea has also been treated with other medications such as 
ondansetron and prochlorperazine (Davis 2009 pp. 357). Haloperidol has been used 
successfully to treat opioid induced delirium (Kalso 2013). 
NSAIDs and paracetamol 
There is no significant variety in side effects among NSAIDs (Furst et al. 2011 pp. 638). 
Common NSAID induced side effects are presented in table 4.  
Table 4. NSAID common side effects (after Furst et al. 2011 pp. 638, Non-steroidal anti-
inflammatory drugs: Käypä hoito -recommendation 2009). 
Target organ Side effect 
Central nervous system Headache, tinnitus, dizziness 
Cardiovascular Fluid retention, hypertension, edema 
Gastrointestinal Abdominal pain, dysplasia, nausea, vomiting, ulcers and 
bleeding 
Pulmonary Asthma 
Skin Rashes, pruritus 
Renal Renal impairment, renal failure, hyperkalemia, 
proteinuria 
Hematologic Prolonged bleeding time 
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The most common NSAID-related side effects are GI-tract adverse effects that include gastric 
ulcers and abdominal pain (Non-steroidal anti-inflammatory drugs: Käypä hoito -
recommendation 2009). NSAIDs also prolong bleeding time by inhibiting thrombocyte 
aggregation resulting in increased risk for bleeding. Thus, NSAIDs are capable of inducing 
life-threatening gastric ulcers. However, COX-2 selective NSAIDs induce ulcers less 
frequently than non-selective NSAIDs due to more selective COX inhibition. NSAID induced 
risk for ulcers is dose dependent and the risk is fivefold in patients using high dose and 
twofold to threefold in patients using medium dose when compared to patients not using 
NSAIDs (Hernández-Diáz & García-Rodríguez 2001a). Almost all NSAID users receive mild 
bleeding in the GI-tract yet it rarely leads into anemia or causes any symptoms (Non-steroidal 
anti-inflammatory drugs: Käypä hoito -recommendation 2009). NSAID use increases the risk 
of developing a hospice care demanding ulcer by three to four fold compared to patients not 
taking NSAIDs. It is suggested to use therapies in prevention of gastric ulcers in patients 
using NSAIDs and PPIs, H2-inhibitors and misoprostole have been used with success. 
However, some evidence supports PPIs and misprostole being more efficient than H2-
inhibitors. NSAIDs have potential interactions with drugs increasing the risk for bleeding 
which are considered in the chapter 6 (Kalso 2009 pp. 183-187). Concomitant use of 
corticosteroids and anticoagulants, age > 70 years old, previous ulcer and overlapping of 
NSAIDs increase the risk for ulcers (Lynch & Watson 2006). 
Risk for renal side effects in patients using NSAIDs is high especially in the elderly (Lynch & 
Watson 2006). No benefit is received using COX-2 selective NSAIDs regarding to the renal 
side effects. NSAID induced renal adverse effects are discussed in more detail in chapter 5.3. 
NSAIDs may increase blood pressure in patients with high blood pressure thus monitoring is 
recommended. In addition, COX-2 selective NSAIDs increase risk for cardiac infarction. 
Hypersensitivity to NSAIDs has been reported infrequently (Kalso 2009 pp. 183).  
Paracetamol is well tolerated and most concerning side effect is hepatotoxicity in high doses 
and when used in chronic alcoholics (Lynch & Watson 2006). Paracetamol induces 
hepatotoxicity through its activation through CYP450 enzymes into N-acetyl-p-benzoquinone 
imine (NAPQI) that causes liver cell death probably by covalent binding to mitochondrial 
proteins that interferes with energy production (James et al. 2003). The toxic metabolite is 
formed if the normal route of paracetamol metabolism into nontoxic metabolites is exceeded. 
However, toxic metabolite is bound by glutathione (GSH) but when the capacity is run out the 
toxic metabolites are formed. Dose of 15 g of paracetamol may be fatal due to liver failure 
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which may be associated with renal toxicity (Furst et al. 2009 pp. 650). Doses more than 4 g 
per day are not recommended at any setting. N-acetylcysteine is used to treat paracetamol 
poisoning which increases the amount of intracellular GSH in the liver cells (Hoppu 2002). 
Malnutrition may lower doses required to induce severe hepatotoxicity due to deficiency of 
required agents in glutathione synthesis (Kurtovic & Riordan 2003). Other paracetamol 
induced side effects are benign GI-tract symptoms such as abdominal pain and diarrhea. 
Antidepressants and anticonvulsants 
Most common side effects of amitriptyline are sedation, dry mouth and weight gain which 
occur in > 30 % of the patients when constipation and orthostatic hypotension occur in 10-30 
% of the patients (Lynch & Watson 2006). However, nortriptyline presents these side effects 
less frequently: dry mouth and constipation occur in 10-30 % of the patients but sedation, 
weight gain and orthostatic hypotension in 2-10 % of the patients. Amitriptyline has the 
strongest anticholinergic activity of all TCAs thus it is capable of inducing urinary retention, 
blurred vision and confusion (Kalso 2009 pp. 205, Haanpää et al. 2010). Especially the 
elderly are susceptible to the anticholinergic side effects, constipation and urinary retention 
induced by TCAs (Kalso 2009 pp. 205). 28 % of the patients treated with TCAs for 
depression withdrew from the treatment due to side effects (MacGillivray et al. 2003). 
The most common side effects of gabapentinoids are somnolence and dizziness (Toth 2014). 
31 % of the patients using pregabalin for neuropathic pain experience dizziness and 22 % 
somnolence which both are dose dependent side effects (Toth 2014). Despite these side 
effects tend to ease over the time, dizziness and somnolence lead to discontinuation of the 
treatment in 3-4 % and 2-3 % of the patients using pregabalin and gabapentin, respectively, in 
patients with neuropathic pain. Less frequent side effects have been reported, such as dry 
mouth, nausea, edema, vertigo, visual blurring, cognitive difficulties and asthenia (Fallon 
2013, Toth 2014). In total 2-4 % of the patients are withdrawn from pregabalin or gabapentin 
treatment due to the side effects (Toth 2014). However, gabapentinoid induced side effects are 
usually mild or moderate. 
Venlafaxine and duloxetine are usually considered superior by their adverse effect profile 
compared to TCAs in neuropathic pain (Lynch & Watson 2006). Yet, venlafaxine and 
duloxetine induce nausea, loss of appetite, hypertension, constipation, sedation, dry mouth 
and anxiety but duloxetine lacks hypertension (Haanpää et al. 2010). Side effects are 
commonly of lower prevalence compared to TCAs (Lynch & Watson 2006). 
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5.3 Decreased renal function 
Decreased renal function is more frequent in the elderly and 67 % of discharged patients with 
creatinine clearance < 10 ml/min had contraindicated prescriptions regarding their renal 
function (Mercandante & Arcuri 2004). Renal impairment is also common among cancer 
patients (Hardy 2009 pp. 69). Some common causes of the renal impairment in patients with 
cancer are presented in table 5. Cancer incidence is higher in the elderly which makes aging 
together with hypertension and diabetes probable reasons leading to renal impairment. 
However, many drugs such as NSAIDs, ACE-inhibitors and some anti-cancer agents may 
induce renal impairment. Some of the opioids or their metabolites are commonly excreted into 
urine while in the elderly these metabolites accumulate and in the worst scenarios may lead to 
respiratory depression (Fine et al. 2004). Impact of renal function on analgesic elimination is 
presented in table 6. 
Table 5. Factors inducing renal impairment in patients with cancer (Lubran 1995, Hardy 2009 
pp. 69) 
Dehydration 
Age-related: hypertension, diabetes, physiological changes 
Paraneoplastic: hypercalcaemia, consumptive coagulopathy 
Drugs: NSAIDs, ACE-inhibitors, anti-cancer drugs (eg. cisplatin, methotrexate), antibiotics 
(gentamicin) 
Treatment-related: tumor lysis syndrome, tumor infiltrating in the kidneys 
Vascular problems: tumor thrombus 
Hepatorenal failure in patients with liver metastases 
 
Opioids 
Influence of renal impairment in morphine elimination is major (Hardy 2009 pp. 71-72). 
M6G, metabolite of morphine, is considered more potent than morphine and is highly 
excreted into urine hence making morphine a risk medicine in patients with kidney 
dysfunction because of risk for respiratory depression (Mercandante & Arcuri 2004, Hardy 
2009, pp. 71-72). However, morphine has individual variation even in people with normal 
kidney function (Hardy 2009 pp. 72). Morphine is recommended to be used with caution in 
patients with renal impairment. 
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Oxycodone has some interindividual variety of elimination in patients with renal dysfunction 
(Kalso 2004, Hardy 2009 pp. 73). Yet, there is some evidence to support that elimination of 
oxycodone and its metabolites, mostly inactive noroxycodone, are reduced in end-stage renal 
impairment patients which may cause more sedation (Mercadante & Arcuri 2004, Hardy 2009 
pp. 74). Thus it is recommended to use oxycodone with caution in patients with renal 
impairment (Hardy 2009 pp. 74). 
Hydromorphone and its active metabolites are excreted into urine thus producing a potential 
risk for increased side effects when used in patients with kidney dysfunction (Mercandante & 
Arcuri 2004). Hydromorphone has been shown to cause more neurotoxic symptoms in 
patients with renal impairment thus it is recommended to use with caution in patients with 
renal impairment (Hardy 2009 pp. 72, Paramanandam et al. 2011). 
Less than 10 % of fentanyl is excreted unchanged into urine which makes it fairly safe to use 
in patients with renal impairment (Mercadante & Arcuri 2004, Hardy 2009 pp. 73). However, 
the controversities in the evidence exist on the clinical impact of fentanyl use in patients with 
renal dysfunction (Mercadante & Arcuri 2004). 
Methadone is probably safe to use in patients with renal impairment yet large variety between 
individuals has been detected (Hardy 2009 pp. 74). Methadone elimination into the urine is 
pH dependent and is excreted more efficiently into acidic urine (Hardy 2009 pp. 74, Renbase 
2015). 
Buprenorphine is mostly eliminated through hepatic metabolism and only 10-30 % is excreted 
into urine (Hardy 2009 pp. 75-76). However, buprenorphine metabolites are excreted into 
urine thus renal impairment may lead to accumulation of metabolites. This is unlikely of 
clinical importance since metabolites are significantly less active than the parent drug. 
Tramadol is highly excreted into urine where 30 % of unchanged parent drug and 60 % as 
metabolites are eliminated through kidneys (Hardy 2009 pp. 72-73). Half-life of tramadol is 
increased by 1.5 – 2 fold in patients with GFR 5-80 ml/min. It is suggested that either dosage 
interval is prolonged or dose is reduced if patients has kidney dysfunction (Mercadante & 
Arcuri 2004, Hardy 2009 pp. 72-73). Maximum dose of tramadol per day in patients with 
GFR 10-30 ml/min is suggested to be 200 mg (Hardy 2009 pp. 72-73, Renbase 2015). 
Codeine is susceptible to genetic variety in CYP2D6 that is also affecting factor to the clinical 
importance of renal dysfunction to codeine (Hardy 2009 pp. 70). For normal metabolizers 
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renal dysfunction is probably of very small clinical importance but in fast metabolizers it may 
be clinically important. However, national Renbase-database suggests that dose reduction 
should be taken under consideration in patients with mild to moderate renal impairment and 
should be avoided if patient has severe to end-stage renal impairment (Renbase 2015). 
Opioids are capable of inducing decreased renal function on their own but the mechanism is 
not well understood (Schumacher et al. 2011 p. 552). It is suggested that opioid induced renal 
impairment is caused by decreased blood flow in the kidneys. 
Table 6. Impact of renal function on analgesic elimination and clinical implications (Bennett 
et al. 1996, Whelton 1999, Mercadante & Arcuri 2004, Hardy 2009 pp. 70-76, Nagler et al. 
2012, Renbase 2015) 
Drug Influence of renal dysfunction Clinical implications 
Morphine Major Use with caution in patients with 
renal impairment, monitor effects 
Oxycodone Significant Use with caution in patients with 
renal impairment 
Hydromorphone Unclear Use with caution 
Fentanyl Minimal Probably safe to use 
Methadone Minimal Interindividual variation 
Buprenorphine Minimal Probably safe to use 
Tramadol Major Dose alteration is recommended, use 
with caution 
Codeine Minimal Interindividual variety in metabolism 
which may affect clinical importance 
of renal clearance 
NSAIDs Major Avoid using in patients with chronic 
renal insufficiency, increases risk for 
toxicity 
Paracetamol Minimal Safe to use in therapeutical doses 
Gabapentinoids Major Dose adjustment recommended 
TCAs Minimal Probably safe to use 
Venlafaxine Major Dose adjustment recommended 
Duloxetine Significant Probably safe in patients with mild to 
moderate renal impairment, avoid in 
patients with severe impairment 
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NSAIDs and paracetamol 
Non-steroidal anti-inflammatory drugs (NSAIDs) are not significantly excreted through 
kidneys yet they are potentially nephrotoxic (Bennett et al. 1996, Whelton 1999). NSAIDs 
may rarely cause serious conditions such as acute renal failure (ARF), sodium retention, 
potassium retention, water retention or acute interstitial nephritis (Bennett et al. 1996). All 
NSAIDs should be avoided in patients with severe kidney dysfunction (GFR < 30 ml/min) 
(Renbase 2015). Also patients with existing risk factors for life-threatening kidney related 
toxicities should be cleared before initiating a NSAID therapy. NSAIDs may lead to acute 
renal failure due to increased vascular tonus in afferent arteria of the glomerulus (Bennett et 
al. 1996). Tonus of the afferent arteria is regulated by prostaglandins that are synthesized by 
COX enzymes but are inhibited by NSAIDs. NSAID withdrawal usually reverses the adverse 
effect. 
Paracetamol is not excreted through kidneys or does it not have renal toxicity when 
therapeutical doses are used (Blantz 1996, Renbase 2015). However, high doses of 
paracetamol may induce nephrotoxicity. 
Adjuvant analgesics 
Gabapentinoids are almost entirely eliminated through kidneys thus dose adjustment is 
required in patients with kidney dysfunction (Randinitis et al. 2003, Renbase 2015). 
Randinitis et al. suggested that dose of pregabalin should be adjusted in every patient with 
GFR < 60 ml/min but Renbase suggests that dose reduce of 25 % should be considered in 
patients with GFR 50-80 ml/min. Half-life of pregabalin may increase by almost 3-fold in 
patients with severe kidney dysfunction (Randinitis et al. 2003). Gabapentin is entirely 
eliminated through excretion in the kidneys thus it is recommended that gabapentin’s dose is 
reduced by 25-50 % when patients have GFR 50-80 ml/min (Miller & Price 2009, Renbase 
2015). Half-life of gabapentin has been reported to rise from 5-7 hours up to 132 hours in a 
patient with renal failure without hemodialysis (Kaufman et al. 2014). 
Tricyclic antidepressants do not require dose adjustment in patients with renal impairment 
(Nagler et al. 2012, Renbase 2015). Elimination of venlafaxine is delayed in patients with 
renal impairment thus it is suggested to adjust dose when necessary to use (Troy et al 1994, 
Renbase 2015). The dose of venlafaxine is recommended to be reduced by 25-50 % 
depending on the stage of renal impairment (Renbase 2015). Dose adjustment is not required 
for patients who use duloxetine with GFR > 30 ml/min (Lobo et al. 2010). However, 
duloxetine is not suggested to be used in patients with severe kidney dysfunction. 
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6. Analgesic interactions 
 
Opioid consumption has increased by sixfold in Finland and a significant increase has also 
been seen in consumption worldwide which produces increased risk for opioid drug 
interactions (Loke et al. 2008, Leppert 2011, Overholser & Foster 2011, Nevantaus et al. 
2013, Jann et al. 2014). Opioids have various interactions which produce risk for potential 
failure in pain management (Strouse 2009, Overlholser & Foster 2011). For instance, opioids 
have increased risk for respiratory depression and sedation when used simultaneously with 
benzodiazepines (BNZ) (Schumacher et al. 2011 p. 556). When opioids are used concurrently 
with other central nervous system affecting drugs risk for falls (Lönnroos 2009) and CNS 
depression is increased (Baxter 2008 pp. 161-187). Opioids have a large variety of 
pharmacokinetic interactions that are mostly due to alteration of activity in cytochrome P450 
enzymes involved in opioid metabolism (Strouse 2009). NSAIDs are a basic analgesic 
regimen for mild cancer pain (WHO 1996) and present potential life threatening interactions, 
among others, with warfarin which increases risk for gastrointestinal bleeding by almost 
fivefold (Delaney et al. 2007). Patients with cancer also frequently suffer from depression 
(Jones 2001) which warrants use of antidepressants such as selective serotonin re-uptake 
inhibitors (SSRIs) (Loke et al. 2008). This arises increased risk for potential interactions for 
gastrointestinal bleeding while SSRIs are used concurrently with NSAIDs. Analgesic 
interactions are summarized in table 8. 
Interactions of analgesics are a risk for failing in pain management (Strouse 2009). There is 
little or none available information on clinical significance of analgesic interactions in 
patients with cancer. However, potential interactions have been shown to occur in 16-63 % of 
patients with cancer when all medications are taken into account (Riechelmann & Del Giglio 
2009). Meta-analysis conducted by Dechanont et al. showed that 1.1 % of all hospital 
admissions are due to drug interactions and NSAIDs are indeed the most common drug 
involved in hospital admissions caused by drug interactions (Dechanont et al. 2014). 
6.1 Opioid pharmacokinetic interactions 
Opioids have various pharmacokinetic interactions (Overholser & Foster 2011). There are 
mainly two P450 enzymes related in opioid metabolism: CYP2D6 and CYP3A4. The 
enzymes related to each analgesic and outcome of metabolism modulation are presented in 
table 8 whereas drugs that are capable of modulating activity of these enzymes are presented 
in table 7. The drugs presenting stronger modulation of the enzymes are more likely to cause 
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interactions that are clinically important. Pharmacokinetic interactions are considered in more 
detail for each drug below. Hydromorphone has very low risk for pharmacokinetic 
interactions because of phase II metabolism and is thus not considered in detail (Overholser & 
Foster 2011). 
6.1.1 Morphine 
Morphine clearance is increased by combined use of oral contraceptives and mechanism is 
suggested to be mediated through increased conjugation of morphine in the liver which leads 
to enhanced clearance (Baxter 2008 pp. 172-173). Diclofenac may reduce the clearance of 
morphine’s active metabolite, M6G, which may increase the risk for respiratory depression 
(Baxter 2008 pp. 178). Simultaneous use of rifampicin may reduce morphine’s analgesic 
effect due to CYP3A4 induction which is one route of morphine metabolism in the liver 
(Fromm et al. 1997). However, Overholser and Foster suggest that there are no evidence to 
support that morphine has P450 enzyme related interactions (Overholser & Foster 2011). 
6.1.2 Oxycodone 
Oxycodone is metabolized mainly through CYP3A4 into an inactive metabolite 
noroxycodone and in lesser extent through CYP2D6 which produces active metabolite 
oxymorphone (Overholser & Foster 2011). If oxycodone is used concurrently with a strong 
CYP 3A4 inhibitor (eg. clarithromycin, erythromycin, fluconazole, ketoconazole and 
voriconazole) increased opioid effects are probable due to higher concentration of oxycodone 
and higher rate of metabolization into the active metabolite. Using oral oxycodone 
concomitantly with a strong 3A4 inhibitor, voriconazole, 3.6 fold increase has been seen in 
oxycodone AUC. Simultaneous use of another 3A4 inhibitor, itraconazole, produced fairly 
lower increase in the oxycodone concentration (Grönlund et al. 2010). However, Grönlund 
and colleagues noticed no difference in pharmacodynamic effects of oxycodone when 
CYP3A4 was inhibited. Controversially, Kummer et al. suggested that strong CYP3A4 
inhibitor, ketoconazole, increased oxycodone’s pharmacodynamic effects including analgesia 
(Kummer et al. 2011). A study conducted by Samer et al. showed consistent information that 
inhibition of CYP3A4 increases oxycodone’s analgesic effects and adverse effects alone and 
especially if the patient is an ultrafast CYP2D6 metabolizer (Samer et al. 2010). In addition to 
CYP3A4 inhibiting drugs, grapefruit may increase concentrations of oxycodone through 
CYP3A4 inhibition in the intestine resulting in higher bioavailability of oxycodone 
(Nieminen et al. 2010). Increased pharmacodynamic effects of oxycodone were slightly 
noticed when grapefruit juice was given to the patients before oxycodone administration. 
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However,  Inhibiting of CYP2D6 (eg. paroxetine, fluoxetine, celecoxib) does not have 
significant effect on oxycodone’s pharmacodynamic effects or concentration on its own but 
when an CYP3A4 inhibitor is added it is very likely of clinical significance (Grönlund et al. 
2010). 
CYP3A4 inducers (eg. phenytoin and rifampicin), on the other hand, may decrease 
oxycodone induced opioid effects and may lead into failure in pain management (Overholser 
& Foster 2011). Rifampicin is inducer for both CYP3A4 and CYP2D6 and it greatly increases 
concentrations of oxycodone metabolites and decreases opioid effects of oxycodone 
especially when oxycodone is administered orally (Nieminen et al. 2009).  
6.1.3 Methadone 
Methadone is metabolized mostly through CYP3A4 which produces high inter-individual 
changes in methadone’s oral bioavailability that ranges between 41 % and 95 % (Ferrari et al. 
2004). Other enzymes involved in methadone metabolism are CYP1A2, CYP2D6 and 
CYP2B6 (Weschules et al. 2008). Also CYP2C9 and CYP2C19 may play some role in 
methadone metabolism but is not well documented. Modulation of activity of these enzymes 
provides potential drug-drug interactions for methadone (Ferrari et al. 2004). Enzyme 
modulators are presented in table 7. 
Inhibition of CYP3A4 is very likely of clinical significance in patients using methadone and 
close monitoring is suggested if concomitant use is necessary (Armstrong et al. 2009). 
Inhibitors associated in increasing methadone’s pharmacological effects through CYP3A4 are 
eg. erythromycin, ciprofloxacin, clarithromycin, diltiazem, ketoconazole and itraconazole. In 
addition grapefruit may inhibit CYP3A4 in the small intestine which may increase 
methadone’s bioavailability. Despite the inhibitory effect on CYP3A4 is shown with all these 
drugs it is not entirely clear whether all of these drugs play a significant role in vivo but 
caution is required when drugs are used concurrently (Weschules et al. 2008). However, 
ketoconazole and fluconazole are very likely to cause clinically significant interaction with 
methadone through inhibiting its metabolism. Fluvoxamine is suggested to be a potent 
inhibitor of CYP3A4, 1A2 and 2C19 and is capable of producing clinically significant 
interaction with methadone by increasing its opioid effects (Weschules et al. 2008). 
Fluoxetine has properties to inhibit CYP3A4, 2D6 and 2C19 which provides hypothesis that 
clinically important interaction is likely to occur between fluoxetine and methadone. 
However, its clinical significance and probability remains unknown. Paroxetine inhibits 
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CYP2D6 which may present a clinically significant interaction with methadone and requires 
attention in clinical practice. 
Rifampicin is a strong inducer of CYP3A4 and inducer of CYP2B6 and causes a clinically 
significant interaction if used simultaneously with methadone by decreasing opioid effects 
(Davis & Quigley 2009 pp. 221-222). Other CYP3A4 inducers that have shown to increase 
methadone metabolism and decrease its analgesic effects are various HIV medications, 
phenobarbital and phenytoin. Methadone itself is a weak CYP3A4 inducer and CYP2D6 
inhibitor which affect its own metabolism and may also affect metabolism of other drugs that 
are dependent on metabolism through these enzymes (Weschules et al. 2008).  
6.1.4 Fentanyl 
Fentanyl is eliminated through hepatic metabolism via CYP3A4 producing high interaction 
potential with drugs modulating CYP 3A4 enzyme activity, see table 7 (Hall & Hardy 2009 
pp. 186). Overholser & Foster suggest that all drugs inhibiting CYP 3A4 produce a clinically 
important interaction with fentanyl (Overholser & Foster 2011). Saari and colleagues showed 
that voriconazole and fluconazole slow elimination of a single-dose fentanyl by 22 % and 16 
%, respectively (Saari et al. 2008). In addition, Saari et al. concluded that the increase in 
fentanyl single-dose can be calculated for transdermal patches which may present even 100 % 
increase in fentanyl concentration with either of these drugs. Also CYP 3A4 inducers produce 
a potential for drug interaction with fentanyl which may increase fentanyl clearance and 
decrease opioid effects probably resulting in failure in pain management (Overholser & Foster 
2011). Thus it is necessary to monitor patients with concomitant use of related enzyme 
modulators to avoid respiratory depression (Saari et al. 2008, Overholser & Foster 2011). 
6.1.5 Tramadol 
Tramadol is partially a prodrug and requires metabolism through CYP2D6 for its active 
metabolite O-desmethyltramadol (M1) to achieve its full analgesic effect since M1 presents 
much higher opioid receptor affinity compared to the parent drug (Leppert 2009). Thus 
tramadol is at risk for pharmacokinetic interactions when CYP2D6 is inhibited and opioid 
effect may not be achieved. Tramadol is metabolized into inactive metabolite through CYP 
3A4 (Overholser & Foster 2011). CYP2D6 inhibitors are presented in table 7 which of strong 
inhibitors are more likely to cause clinically important interactions with tramadol, eg. 
fluoxetine and paroxetine. However, tramadol has properties to inhibit reuptake of serotonin 
and norepinephrine which are mediated through the parent drug (Leppert 2009). Enzyme 
inhibition may thus increase the concentration of tramadol resulting in increased serotonergic 
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effects (Overholser & Foster 2011). For instance, risk for serotonergic addition is especially 
high if tramadol is used with paroxetine which both inhibits CYP2D6 and also inhibits 
serotonin reuptake in presynaptic nerve. 
6.1.6 Codeine 
Codeine is generally thought to mediate its analgesic effect through its metabolite, morphine, 
which consists 2-5 % of all metabolites (Armstrong & Cozza 2003). Codeine is partly 
metabolized via CYP2D6 into morphine yet other metabolism routes are CYP3A4 into 
norcodeine and UGT2B7 into codeine-6-glucuronide (C6G). There are a variety of 
interactions for codeine because of CYP2D6 dependent mechanism of action and its 
modulators, see table 7 for CYP2D6 inhibitors.  SFINX-interaction database suggests several 
major interactions for codeine and CYP2D6 inhibitors due to decreased analgesic effect of 
codeine (SFINX-PHARAO -database 2015). Nevertheless, some studies have shown that 
despite CYP2D6 is inhibited with a strong inhibitor and morphine concentration is low, 
patients receive analgesia from codeine (Armstrong & Cozza 2003, Lötsch et al. 2006). 
Patients who are fast metabolizers in CYP2D6 show higher concentrations of morphine after 
codeine administration which may produce increased opioid effects (Overholser & Foster 
2011). This is especially important if CYP3A4 is inhibited resulting in bigger proportion of 
codeine metabolized through CYP2D6.  
6.2 Opioid pharmacodynamic interactions 
 
6.2.1 CNS depression 
The most important pharmacodynamic interactions with opioids occur with sedatives and 
hypnotics which induce increased risk for lethal respiratory depression (Trevor & Way 2011 
p. 385). Opioids used concomitantly with sedative drugs may additively increase overall 
sedation (Baxter 2008 pp. 161-187). Both opioids and benzodiazepines are capable of 
inducing sedation and respiratory depression in patients via different pharmacological 
mechanisms (Jann et al. 2014). Similar effect between concomitant use of alcohol and opioids 
has been shown. Additive sedation was noted in patients who received diazepam and 
buprenorphine and was also seen in 68 % of the patients who received midazolam and 
morphine (Baxter 2008 pp. 161-187). Incidence of deaths related to concurrent use of 
benzodiazepines and opioids has increased in general population (Jann et al. 2014). Diazepam 
and alprazolam have induced several deaths in patients on methadone by either 
pharmacodynamic addition or pharmacokinetic modulation (Weschules et al. 2008). 
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Table 7. Drugs available in Finland that modulate opioid metabolism through P-450 enzymes 
(Overholser & Foster 2011, Duodecim-medication database 2015). 
CYP 2D6 
inhibitors 
CYP 3A4 
inhibitors 
CYP 2B6 
inhibitors 
CYP 3A4 
inducers  
CYP 2B6 
inducers 
Amiodarone* 
Bupropion 
Amiodarone* 
Chloramphenicol 
Clopidogrel 
Ticlopidine 
Carbamazepine 
Dexamethasone 
Carbamazepine 
Efavirenz 
Celecoxib 
Chlorpromazine 
Citalopram 
Clemastine 
Diphenhydramine 
Doxepin” 
Doxorubicin” 
Dronedarone 
Duloxetine” 
Ciprofloxacin 
Clarithromycin* 
Diltiazem* 
Dronedarone 
Erythromycin* 
Fluconazole* 
Fluoxetine 
Fluvoxamine 
Gestodene 
Voriconazole Efavirenz 
Modafinil 
Nevirapine 
Oxcarbazepine 
Phenobarbital 
Phenytoin* 
Rifabutiini 
Rifampicin* 
St. John’s wort 
Nevirapine 
Phenobarbital 
Phenytoin 
Rifampicin 
Escitalopram” 
Fluoxetine* 
Haloperidol 
Hydroxyzine 
Levomepromazine 
Methadone 
Metoclopramide 
Paroxetine* 
Perphenazine 
Itraconazole* 
Ketoconazole* 
Mifepristone 
Nelfinavir 
Norfloxacin” 
Ritonavir 
Saquinavir 
Telithromycin 
Verapamil* 
   
Quinidine* 
Ritonavir 
Voriconazole*    
Sertraline 
Terbinafin* 
    
* = strong effect, “= weak effect or limited evidence. 
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However, additive sedative effect can also be seen when opioids are used together with 
neuroleptics, eg. levomepromazine, as well as barbiturates and tricyclic antidepressants. 
Gabapentinoids and sedative antihistamines also enhance opioid induced sedation. 
Pharmacodynamic interactions are presented in table 8. 
6.2.2 Serotonergic effects 
Tramadol produces serotonergic effect which may lead to serotonergic syndrome when used 
concomitantly with antidepressants (Baxter 2008 pp. 187). Rastogi et al. suggest that also 
fentanyl, methadone, dextromethorphan and even oxycodone produce serotonergic effects 
(Rastogi et al. 2011). Effect is probably mediated through weak reuptake inhibition or 
increased release of serotonin into synaptic space. A review conducted by Koury et al. 
showed that incidence of concomitant use of fentanyl with a serotonergic agents associated 
serotonin syndrome is very rare with frequency of 0.09 % (Koury et al. 2015). However, the 
risk for serotonin syndrome is increased with combined use of the mentioned opioids and a 
known serotonergic drug. Serotonin syndrome has been reported with concomitant use of t.d. 
fentanyl and ondansetron. Serotonin syndrome may be caused by concomitant use of 
methadone and MAO inhibitors (Weshcules et al. 2008). This information shows that these 
opioids should be monitored for symptoms of serotonin syndrome especially when used 
together with other serotonergic agents (Rastogi et al. 2011). Nevertheless, evidence is not 
entirely convincing and the mechanism of the interaction is not fully discovered. 
Pharmacodynamic interactions are presented in table 8. 
6.2.3. Additive analgesia 
Opioid-opioid combination has provided beneficial effects in some cases but the evidence to 
support use of combination is controversial (Baxter 2008 pp. 179). Some of the studies 
suggest that two opioids provide pain relief with lower doses and fewer adverse effects 
whereas some studies suggest that adverse effects are more prevalent and even acute opioid 
tolerance has been reported. Partial opioid agonists (eg. buprenorphine) may cause 
withdrawal symptoms if initiated in patient with long-term strong opioid treatment. Thus 
partial agonist may inhibit opioid effect and should be avoided in patients who use strong 
opioids. NSAIDs used together with opioids enhance the analgesic effects without increased 
adverse effects (Baxter 2008 pp. 177-178). For instance, this additive analgesia has been seen 
with methadone and a NSAID which has been seen in cancer patients suffering from visceral 
or bone pain (Weschules et al. 2008). A positive interaction between morphine and 
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gabapentin has been shown where gabapentin may increase the analgesic effect of morphine 
(Baxter 2008 pp. 163). 
6.2.4 Other 
Bradycardia and hypotension have been reported when opioids are used together with calcium 
channel blockers but the mechanism is not well known (Baxter 2008 pp. 168). Methadone has 
QT-prolongation properties which may result in torsades de pointes when used together with 
medications with same property, eg. macrolides or some fluoroquinolones (Weshcules et al. 
2008). 
Ondansetron has shown to reduce analgesic effect of tramadol probably due to serotonin 
receptor inhibitory effect and may require increase of tramadol dose to maintain its analgesic 
effect (Baxter 2008 pp. 161-162). Thus ondansetron is not the drug of choice for an 
antiemetic for patients who receive tramadol for pain. 
6.2 NSAID 
Non-steroidal anti-inflammatory drugs (NSAIDs) present a variety of potential drug 
interactions which may be life-threatening (Delaney et al. 2007, Loke et al. 2008, Horn 2011 
pp. 1160). NSAID interactions are presented in table 8. NSAIDs have a clinically significant 
interaction with antihypertensives, especially with ACE-inhibitors and ATR-blockers, which 
results in decrease of their antihypertensive effect and requires intensification of the 
antihypertensive treatment (Fournier et al. 2012). 
Bleeding 
All NSAIDs have a potential interaction with antithrombotics which may result in severe GI 
bleeding and its clinical significance is well-known (Delaney et al. 2007). Adjusted rate ratios 
for GI bleeding when warfarin is used concomitantly with NSAIDs, ASA, or COX-2 selective 
NSAIDs are 4.79, 6.48 and 4.62 respectively. Similar but lower risk may be seen with 
clopidogrel. When clopidogrel is used simultaneously with NSAIDs, ASA or COX-2 
selective NSAIDs the adjusted risk ratios for GI bleeding are 2.9, 2.6 and 3.9 respectively. 
The risk for gastric bleeding is multiplied in case of concomitant use compared to all drugs 
used as monotherapy. Previous data do not include over-the-counter (OTC) NSAIDs. 
Increased use of (selective serotonin re-uptake inhibitors) SSRIs lead to a higher risk of 
potential interactions with concomitant use of NSAIDs (Loke et al. 2008, Auerbach et al. 
2013). Interaction between NSAIDs and SSRIs is well documented and Loke and colleagues 
showed in their meta-analysis that interaction produced a highly increased risk for upper 
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gastric hemorrhages (Loke et al. 2008). The risk for bleeding gastric ulcers is doubled when 
using SSRI as monotherapy but when NSAID is added the risk is increased by fivefold 
compared to patients having neither of these medicines. Risk is escalated in the older 
population since they are more sensitive for these adverse effects. Estimates for number 
needed harm (NNH) are 312 per year for SSRI alone and 82 per year for SSRI and 
concomitant NSAID. The mechanism of increased risk for GI bleeding is probably mediated 
through altered serotonin levels in platelets resulting in impaired platelet aggregation. 
When NSAIDs are used concomitantly with either low-dose or anti-inflammatory dose of 
ASA the risk for bleeding gastric ulcers is increased by 7.7-fold and 8.4-fold, respectively 
(Baxter 2008 p. 142-145). In addition, NSAIDs may block ASA’s positive cardioprotective 
effect via competition in binding to COX-1 enzyme where ASA binds irreversibly and other 
NSAIDs bind reversibly. If other NSAID is present with high quantities when ASA is 
administered it is possible that NSAID block ASA induced antiplatelet effect. 
Several studies have shown an interaction between NSAIDs and corticosteroids resulting in 
gastric ulcers (Baxter 2008 p. 1058). Higher risk for gastric ulcers is well documented and the 
relative risk varies between tenfold and 15-fold in patients of 60-year-old or older who use 
NSAIDs together with corticosteroids when compared to patients not using either of the 
drugs. Hernández-Díaz and García-Rodríguez showed similar results in patients using 
corticosteroids with low to medium or high doses of NSAIDs and noticed odds ratios for 
gastric ulcers were 4 and 12.7, respectively (Hernández-Díaz & García Rodríguez 2001b). 
Older patients are more sensitive to NSAID side effects and to interaction with corticosteroids 
(Baxter 2008 pp. 1058). In addition, history of previous gastric ulcers increase the risk for 
gastric ulcers when NSAIDs and corticosteroids are used simultaneously. 
Renal 
NSAIDs have a clinically significant interaction due to their mechanism of action with ACE-
inhibitors leading to renal impairment (Horn 2011 p. 1160). Nonsteroidal anti-inflammatory 
drugs (NSAIDs) initiate their mechanism of action through inhibition of COX1 and COX2 
enzymes which are present in prostaglandin synthesis (Bennett et al. 1996, Furst et al. 2011 p. 
637). Prostaglandins increase the tone of afferent arteria in the glomerulus. ACE-inhibitors 
and ATR-blockers at the same time inhibit angiotensin dependent tone regulation of efferent 
arteria in the glomerulus which is the probable mechanism for the interaction (Nygård et al. 
2012). However, some studies suggest that there is no interaction between NSAIDs and ACE-
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inhibitors leading to kidney impairment but is instead caused by either of these drugs per se 
and is more likely related to long half-life of the NSAID (Strümer et al. 2001, Huerta et al. 
2005). Controversially, Adhiyaman and colleagues showed in their study that concurrent use 
of NSAID and ACE-inhibitors are one of the main causes leading to renal impairment in the 
elderly (Adhiyaman et al. 2001). This is in align with study conducted by Nygård et al. who 
showed that NSAID combined with either diuretic or ACE-inhibitor/ATR-blocker decreased 
patient’s renal clearance (Nygård et al. 2012). 
Pharmacokinetic interactions 
Some NSAIDs are associated with accumulation of methotrexate due to decreased renal 
excretion of methotrexate (Baxter 2008 pp. 8). For instance, ibuprofen may decrease 
clearance of methotrexate by 40 - 60 % which may result in serious mehotrexate toxicity 
(Baxter 2008 pp. 649-650). In general NSAIDs should be used with caution in patients with 
small-dose methotrexate but avoided in patients with high-dose methotrexate (Baxter 2008 
pp. 649-651, Kalso 2013 pp. 886). 
Absorption of some acidic NSAIDs may be increased while simultaneous administration with 
magnesium hydroxide due to better solubility of NSAIDs in the gastric fluids (Baxter 2008 
pp. 141). Also, fluconazole may increase celecoxib concentration even by 130 % due to 
CYP2C9 inhibition and increase the peak concentration by 60% resulting in increased adverse 
effects (Baxter 2008 pp. 145). 
6.3 Paracetamol 
Paracetamol is a safe analgesic drug in therapeutic doses and its elimination occurs via 
glucuronidation and sulfation metabolism in liver (Correia 2011 pp. 60-61). However, if the 
dose is highly exceeded the non-toxic metabolic routes glucuronidation and sulfation are 
saturated which leads into a situation where paracetamol is metabolized via CYP enzymes 
into toxic N-azetylbenzoiminoquinone. The toxicity of the metabolite is targeted to both liver 
and kidney (Furst et al. 2011 pp. 650). Glutathione (GSH) is capable of conjugating the toxic 
metabolite yet once its reservoir is completely consumed the toxic metabolite is free to do its 
damage (Correia 2011 pp. 60-61). 
Ethanol paracetamol interaction is well-known and it is usually due to chronic ethanol 
consumption (Masters 2011 pp. 395). This is result from ethanol’s tendency of induction of 
CYP450 enzymes which onwards metabolize paracetamol into its toxic metabolite. 
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Nonetheless, acute ethanol consumption may result in decreased activity of some CYP450 
enzymes thus not leading to increased risk for paracetamol toxicity. Interaction between 
paracetamol and CYP450 enzymes inducing drugs including epileptics such as carbamazepine 
and phenytoin is described with decreased analgesic effect of paracetamol and also with 
increased risk for toxicity of paracetamol (Baxter 2008 pp. 191). However, debate on clinical 
significance of the interaction is conflicting but it is suggested that paracetamol would be used 
with caution in patients using certain CYP450 inducing drugs. 
Onset of paracetamol’s absorption is highly dependent on emptying of stomach where 
anticholinergics may delay onset of analgesic effects of paracetamol due to delay of emptying 
of stomach (Baxter 2008 p. 192). Similar effect has been shown to occur when used 
simultaneously with opioids (Baxter 2008 p. 196). 
Oral contraceptives alter paracetamol pharmacokinetics by increasing its clearance by over 60 
% and decrease its elimination half-life by 30 % whereas paracetamol increase absorption of 
ethinylestradiol by 20 % but the clinical significance remains unknown (Baxter 2008 p. 195). 
Stockley’s interactions suggest that antiemetic ondansetron has inhibitory effects on 
paracetamol analgesia due to its 5-HT3 receptor affinity (Baxter 2008 p. 195) but Jokela and 
colleagues suggest that ondansetron would not have clinically significant negative impact on 
paracetamol analgesia (Jokela et al. 2010). It is shown that tropisetron, similar to ondansetron, 
blocks the analgesic effect of paracetamol. On the other hand, Ramirez and colleagues 
showed that interaction between paracetamol and ondansetron was clinically important in 
children after tonsillectomy (Ramirez et al. 2014). The information available on interaction of 
paracetamol and ondansetron is controversial and warrant more studies. 
Paracetamol interacts with warfarin even with low dose (2 g / day) and increases INR value 
significantly (Zhang et al. 2011). The increase of the INR is dose dependent and INR 
monitoring is suggested in patients taking paracetamol concomitantly with warfarin because 
warfarin dose adjustment may be required. 
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Table 8. Analgesic interactions, mechanisms and outcomes (Delaney et al. 2007, Loke et al. 2008, Glare 2009 pp. 131, Quigley & Glare 2009 pp. 247, Strouse 2009, Kalso 
2013 pp. 788, Overholser & Foster 2011, Schumacher et al. 2011 pp. 556, DeBattista 2011 pp. 536-537, Micromedex-database 2015, SFINX-PHARAO -database 2015). 
Drug Pharmacokinetic Pharmacodynamic 
Inhibition Outcome Induction Outcome Drugs Outcome 
Codeine CYP2D6 decreased analgesic effect CYP2D6 
(polymorfism) 
increased analgesic 
effect 
CNS depresssants§ sedation, respiratory 
depression 
Tramadol CYP2D6 decreased analgesic effect CYP3A4 decreased analgesic 
effect 
SSRI, SNRI, triptanes 
 
CNS depressants§ 
serotonin syndrome 
 
CNS depression* 
Oxycodone CYP3A4  
 
 
 
CYP2D6 
increased opioid effects and 
increased risk of respiratory 
depression 
 
decreased analgesic effect 
CYP3A4 decreased analgesic 
effect 
CNS depressants§ CNS depression* 
Morphine CYP3A4 no likely clinical 
significance 
CYP3A4 no likely clinical 
significance 
CNS depressants§ CNS  
depression * 
Fentanyl CYP3A4 increased risk for side 
effects 
CYP3A4 decreased analgesic 
effect 
CNS depressants§ CNS depression* 
Methadone CYP3A4 
 
CYP2D6 
increased risk for side 
effects 
increased risk for side 
effects 
CYP3A4 decreased analgesic 
effect 
CNS depressants§ CNS depression* 
Hydromorphone - - - - CNS depressants§ CNS depression* 
NSAID - - - - antithrombotics, SSRIs 
 
ACE inhibitors, ATR-
blockers 
increased risk for 
bleeding 
increased risk of 
AKI 
Gabapentinoids - - - - CNS depressants§ Sedation 
TCA CYP2D6 increased risk for side 
effects 
- - Anticholinergics urinary retention, 
dry mouth 
Paracetamol - - - - - - 
SSRI= selective seretonin re-uptake inhibitors, NSAID= non-steroidal anti-inflammatory drugs, TCA= trisyclic antidepressants, *= symptoms of CNS depression: sedation, respiratory 
depression, cognitive impairment, impairment of motor function, §= antidepressants, neuroleptics, benzodiazepines, central muscle relaxants, anxiolytics
 
 
7. Adherence to pain management 
 
Medication adherence is defined as whether the patient uses medications according to health 
care professional’s instructions and as a term it is trying to describe patient’s medication-
taking behavior (Osterberg & Blaschke 2005). Term “compliance to medication” has also 
been widely used to describe medication-taking behavior. Rates for medication adherence 
have varied between 43 – 78 % for long-term treatments although the acceptable rate of 
adherence is considered to be 80 – 95 % depenging on condition (Osterberg & Blaschke 
2005).  
7.1 Assessment of medication adherence 
None of the various medication adherence assessment methods has formed into a golden 
standard of practice (Lehmann et al. 2014). Lehmann and colleagues suggest that assessment 
of medication adherence should be a part of medication reviewing for patients with chronic 
diseases. None of the measures to assess medication adherence show adequate validity and 
reliability in conjunction with sensitivity to detect changes in medication adherence 
(Lehmann et al. 2014). The most used measures are self-reports, electronic measures and 
pharmacy refills. All methods have advantages and disadvantages which are considered as 
follows. 
Direct methods to assess adherence include medication, metabolite or specific marker 
detecting in urine or blood samples (Lehmann et al. 2014). Methods are accurate but stressing 
for patients and usually expensive. These methods are capable of detecting if the patient has 
administered the medication. 
Interviews, questionnaires and diaries are the most used methods to assess medication 
adherence in the clinical practice because of easy use and low cost (Lehmann et al. 2014). 
Self-reports are also capable of detecting the difference between intentional and unintentional 
nonadherence. Self-reports usually overestimate adherence to medication and have difficulties 
in detecting poor adherence. If a self-report method is used, it is important to validate the 
instrument to use by comparing it with some other method of assessment. Risk for lack of 
sensitivity and false positive results are common due to patient forgetfulness and social 
approval which highly affect the answers to reports. 
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Electronic methods include certain devices developed to study medication adherence or 
record patients’ medication taking behavior (Lehmann et al. 2014). Devices record date and 
time when the package is opened presuming that the medicine is administered. Electronic 
methods record longitudinal medication intake, are repeatable and are sensitive to changes in 
medication taking behavior. Electronic methods are capable of addressing changes in 
medication intake before and after physician appointment. 
Pharmacy refill recording can be used for large studies yet it does not reflect the daily 
adherence to medications but the adherence in a larger perspective (Lehmann et al. 2014). 
Pharmacy refill recording is not applicable if patient goes to multiple pharmacies. Pill count 
recording is simple pill counting and compares how many pills have been taken in respect to 
how many should have been taken. 
Morisky medication adherence scale 
Morisky’s 4-item medication adherence scale (MMAS-4) has been presented in 1986 to 
assess adherence to medication and was originally developed to assess adherence to 
antihypertensive therapies (Morisky et al. 1986). The same scale has been used to assess 
adherence to cancer pain medication with excellent reliability and validity in Taiwan (Tzeng 
et al. 2008). MMAS-4 is a simple four-item questionnaire that is easy to conduct in clinical 
practice and has also been used to assess adherence to antiretroviral therapy in HIV patients. 
However, MMAS-4 is not reliable in measuring missed doses when used as the only 
assessment method. Questions in MMAS-4 (Morisky et al. 1986): 
1. Do you ever forget to take your medicine? 
2. Are you careless at times about taking your medicine? 
3. When you feel better do you sometimes stop taking your medicine? 
4. Sometimes if you feel worse when you take the medicine, do you stop taking it? 
Barriers questionnaire 
Barriers questionnaire was developed to assess beliefs that patients have toward analgesics 
which may affect the medicaion adherence (Gunnarsdottir et al. 2002). The questionnaire has 
been shown to be both reliable and valid in measuring patient-related barriers to medication 
adherence. It has been shown that patients who do not use medications according to 
prescription get higher score in the barriers questionnaire. Also patients who score high in 
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barriers questionnaire are more likely to be undertreated regarding to their pain and are less 
adherent to their pain medications (Ward et al. 1993, Oldenmenger et al. 2009). 
7.2 Adherence to pain medications 
Under-treatment of cancer pain is a global problem (Deandrea et al. 2008). One of the factors 
resulting in under-treatment of cancer pain is poor adherence to pain medications (Valeberg et 
al. 2008). Valeberg and colleagues showed in their study that 46 % of the cancer outpatients 
were not adherent to their pain medication and only 21 % of the patients were highly adhered 
to their pain medications when all pain medications were included (Valeberg et al. 2008). 
However, Miaskowski and colleagues suggested that 84.5 – 90.8 % of outpatients using 
around-the-clock opioids were adherent to pain medication yet only 22.2 – 26.6 % of the 
outpatients were adherent to per needed pain medications (Miaskowski et al. 2001). Rates for 
high adherence to antihypertensives and medications used to hyperlipidemia were 43 % and 
36.7 %, respectively, which are somewhat higher than results in Valeberg’s study (Morisky et 
al. 1986, Sung et al. 1998, Valeberg et al. 2008). Approximately 43 % of the patients taking 
anticonvulsants or antidepressants for neuropathic pain are adherent to their medications 
(Gharibian et al. 2013). Low adherence to pain medication decreases quality of life and may 
increase society’s health care costs due to increased rate of emergency visits (Graziottin 
2011).  
7.3 Factors affecting medication adherence 
Osterberg & Blaschke presented various factors that predict poor adherence to medications: 
psychological problems especially depression, cognitive impairment, asymptomatic disease, 
inadequate follow-up plan, medication side-effects, lack of trust in medication, lack of 
information of the disease, poor patient-physician relationship, barriers to medications, 
complex treatment and financial concerns (Osterberg & Blaschke 2005). However, predictors 
for good adherence to pain medications are opioid use, more severe pain and male sex 
(Valeberg et al. 2008). 
Patients have a large variety of misbeliefs that affect their medication taking behavior 
(Gunnarsdottir et al. 2002). Many patients fear that analgesics used for cancer pain produce 
addiction which may be a misunderstanding between psychological dependence and 
physiological dependence. Tolerance for analgesic effect is also a common misbelief in 
cancer patients and patients may think that if the medication is started too early there is 
nothing left to relieve the pain in the later phase of the disease. This may be a result from lack 
of information that there is no limit for opioid dose. Often patients believe that side effects are 
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frequent and unmanageable (Gunnarsdottir et al. 2002) hence fear for side effects is one of the 
most important reasons for failure in pain management (Meuser et al. 2001). Fatalism means 
thinking that pain is an inevitable part of the disease and there is no way to manage it which is 
also common in patients with cancer (Gunnarsdottir et al. 2002). Patients with old age, low 
education and low income are more likely to have concerns regarding the use of analgesics 
(Ward et al. 1993). 
Patients hesitate to report their pain due to misbelief that good patients do not complain about 
pain (Gunnarsdottir et al. 2002). Also patients think that pain may distract physician from 
treating the disease thus resulting in reluctance of discussing the pain with the physician. 
Some patients think that pain is a symptom of disease progression which is difficult to admit 
to themselves or to others and are not willing to report of pain. In addition, some patients may 
believe that analgesics are administered through intramuscular injections leading to reluctance 
to report pain if patient fears injections. Patients undergoing active cancer treatment are more 
reluctant to report from their pain to the health care provider (Sun et al. 2007). 
A study conducted by Potter et al. showed that 75 % of the cancer patients have fear for 
addiction, 71 % have concerns about side effects and 55 % concerns about tolerance towards 
pain medications (Potter et al. 2003). Patients had beliefs that hindered their communication 
of pain with physician which of 73 % thought that pain is a symptom of disease progression, 
50 % thought that reporting of pain will distract the physician from treating the disease, 47 % 
did not report pain because they wanted to be “good patients” and 46 % reported fatalism. In 
addition, one study showed that there was a statistically significant correlation between 
negative beliefs about opioids and low rate of adherence to analgesics (Liang et al. 2013). 
The factors hindering adequate pain management may vary between different age groups 
where older patients are more likely to have misbeliefs about analgesic use and are less likely 
to discuss the pain with the physician (Closs et al. 2009). The misbeliefs that are emphasized 
in the elderly include the conception that analgesics should be taken only when necessary and 
when the pain is very severe. Likelihood to talk about the pain to the physician was correlated 
to understanding that physician would get impatient if patient complains about the pain. 
Patients and medication adherence has been extensively studied in patients with chronic pain 
conditions (Graziottin et al. 2011).  Factors that have not been described in reviews 
concerning cancer pain are inadequate knowledge of the disease, unrealistic expectations for 
analgesics, frequent dosing, received pain relief, financial problems and loneliness. These 
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factors are presented in table 9. More frequent analgesic administration results in higher 
incidence of missed doses. Graziottin et al. also suggest that depression is one of the strongest 
factors hindering adherence to analgesic therapy. 
Table 9. Factors affecting negatively to adherence to pain medication in chronic pain and 
suggestions for improving adherence to opioids (modulated from Graziottin et al. 2011).  
Negative factors Suggestions to improve adherence 
Inadequate knowledge of the disease Prognosis of the disease should be explained 
to the patient 
None or mild received benefit from the 
medication 
Adequate management follow-up 
Unrealistic expectations for pain relief Discussion with the patients about objectives 
with pain medication and its schedule 
Patient’s feeling that they cannot manage 
with the pain medication 
Support from relatives; helping with dosing 
of the medication or reminding of dosing 
schedule 
Frequent dosing Simplify dosing 
Anxiety and/or depression Management of depression 
Lack of trust toward the physician Taking the patient’s wishes into account 
when planning the management 
Empathy toward the patient’s pain 
Fear of side effects Side effects should be explained to the patient 
and be treated pro-actively 
Education about medications to the patient 
and the nursing personnel. Information about 
chronic pain and medication side effects. 
Loneliness Support within the community 
 
Physician related barriers are highly affecting the outcome of pain management in patients 
with cancer (Gunnarsdottir et al. 2003). Physician related barriers include factors such as 
inadequate knowledge about the use of analgesics, prevalence of side effects, side effect 
management and negative attitudes toward cancer pain management. Inadequate assessing of 
pain is a result from inconsistent use of pain rating scales, incomplete observation of patient’s 
pain in conjunction with query and incomplete documentation of assessments. Studies that 
have compared physician rated pain scales with patient rated scales have resulted in 
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underestimation of the pain by the physicians. Also inadequate analgesic prescription has 
been shown to occur in patients with cancer pain and even 42 – 65 % of the patients received 
inadequate analgesic for pain, eg. NSAID for severe pain. Inadequate analgesic prescribing 
occurs more commonly in females than in males. 
7.4 Interventions to enhance poor medication adherence 
A Cochrane review concluded that improving medication adherence would have a greater 
impact in clinical outcomes than advances in new therapies (Haynes et al. 2008). Medication 
adherence can be enhanced with four distinct methods: patient education, improved dosing 
schedules, increased clinic open hours and improved communication between physicians and 
patients (Osterberg & Blaschke 2005). Education on medication management includes 
education of patient, relatives and health care providers. Dosing interventions include for 
instance pill-boxes and reduced frequency of dosing. Patients who miss clinic appointments 
are frequently those who are in the greatest need of interventions to improve adherence to 
medications and would benefit from long opening hours. An effective strategy to improve to 
improve medication adherence is to enhance patient-physician communication.  
Also other strategies have been suggested to improve adherence to opioid medications in 
chronic pain patients, presented in table 10 (Graziottin et al. 2011). These suggestions are 
readily aimed to revoke patients’ misbeliefs concerning opioid medications. Barriers and 
misbeliefs in Graziottin colleagues’ review are mostly similar with studies concerning cancer 
pain (Osterberg & Blaschke 2005, Oldenmenger et al. 2009, Graziottin et al. 2011). 
There has been a variety of studies concerning interventions to improve medication adherence 
but not much evidence has been shown to support efficacy of any method to enhance 
adherence (Nieuwlaat et al. 2014). However, Nieuwlaat and colleagues concluded that some 
methods show potential in enhancing adherence. It has been generally assumed that patient 
education increases adherence to pain medication and thus reduces pain intensity and 
increases quality of life (Bennett et al. 2009). Bennett and colleagues showed in their meta-
analysis that there is no evidence to support correlation between patient education and 
increased adherence to analgesic therapy. However, some studies have found evidence that 
patient education would increase adherence rate to analgesics (Oldenmenger et al. 2009). The 
studies in Bennett and colleagues’ meta-analysis used mostly education leaflets or other 
written education for education (Bennett et al. 2009). Despite no improvement in adherence 
was seen by patient education, it reduced pain by 1.0 point in scale of 0-10. Oldenmenger et 
53 
 
al. found in their study that pain education program (PEP) and pain consultation used together 
both increased adherence to analgesic and decreased pain intensity in oncology outpatients 
(Oldenmenger et al. 2011). PEP that was used included education on basic information of 
pain and pain management, recording a pain diary and how to contact health care provider in 
case of need (de Writ et al. 1997). The original PEP showed similar results in decrease of pain 
intensity in cancer patients. In addition, a study conducted in Taiwanese patients focused on 
education targeted to both patients and relatives which showed increased adherence to 
analgesics and decreased level of the worst pain compared to the control group (Lin et al. 
2006).  
Impact of financial problems in adherence to pain management has been overcome in Finland 
by reimbursement system which pays for strong opioids to the patient with cancer (legislation 
for medical incurance 1224/2004, regulation of the Council of the State 25/2013). 
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8. Aims of the study 
 
Primary aims: 
- Determine the rate of adherence and probable reasons for poor adherence in cancer 
outpatients 
- Determine prevalence of clinically important analgesic drug interactions 
Secondary aims: 
- Conduct a medication review to all patients attending the study 
- Determine frequency of implemented recommendations of the medication reviews 
- Evaluate effect of the implemented recommendations on patients’ pharmaceutical care 
issues 
9. Materials and methods 
9.1 Clinic and patients 
Research was conducted between 27
th
 of October 2014 and 30
th
 of January 2015 in a cancer 
outpatient clinic of Kuopio University Hospital. Follow-up study was conducted between 23
rd
 
and 27
th
 of March 2015. In this clinic cancer patients receive their intravenously administered 
cancer therapies. Patients attending to this clinic do not include patients with haematologic 
cancers. Most of the patients live at home and come to have their treatments during the day. 
30-60 patients are treated in the clinic each day. Clinic also gives treatments to patients who 
receive infusion treatments for other medical conditions such as rheumatic diseases. Clinic 
staff includes clinic pharmacist, two physicians, approximately 10 nurses and one treatment 
planner. 
Sample size was determined to be 30-40 patients. Inclusion criteria were determined to be: 
adult patients who used an opioid on regular basis or were prescribed a regular opioid, had in 
total 6 or more regular medications including anticancer therapies, took care of their own 
medications and were undergoing active cancer therapy. 
9.2 Ethics committee approval and the application process 
Approval of The Research Ethics Committee of North Savo Hospital District was granted for 
the study. Also organization permission was granted for the study. 
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The Research Ethics Committee of North Savo Hospital District required following 
documents appropriately filled for applying for approval for the study: 
 Statement application (template filled appropriately) 
 Original research plan 
 Evaluation on ethical aspects of the research (written by person responsible for the 
research) 
 Patient fact sheet 
 Patient agreement form 
 Register caption of scientific research 
9.2.1 Research plan 
Application for approval of ethics committee started with the research plan. Research plan for 
the study consisted of review of literature to support the need for the study and actual plan for 
the research. Research part included brief chapters for aims of the study, materials and 
methods, result analysis, exploits of results, list of research team members, timetable and 
bibliography. 
9.2.2 Evaluation on research’s ethical aspects 
The person responsible for the research wrote an evaluation on research’s ethical aspects. 
Evaluation concerned that patient rights were taken into account in the study. Patient safety, 
risks and benefits were evaluated as well as voluntariness of agreement to participate the 
study. 
9.2.3 Patient fact sheet 
Patient fact sheet was written according to instructions of The Research Ethics committee. 
Fact sheet included information on general aspects of study, aims of the study, risks and 
benefits for the patient, voluntariness of participating and privacy protection. Fact sheet 
contained information on number of patients included to the study and the inclusion criteria 
for the study. The person responsible for the study and clinical associate (chief physician) 
were mentioned in the fact sheet. Contact information of the researcher and the responsible 
person were written in the fact sheet. Ethics committee required patient fact sheet to contain 
information exactly as it was in the research plan. 
9.2.4 Patient agreement form 
Agreement form was written according to instructions of The Research Ethics committee. 
Agreement form was signed by every patient stating that they free-willingly participate in the 
56 
 
study and have read the patient fact sheet. Patient’s date of birth and home address were 
included in the agreement form. Researcher signed the agreement form after receiving it and 
gave the patient a copy of agreement form after the interview. 
9.2.5 Register caption of scientific research 
Register caption was required to be filled appropriately with signatures. Register caption 
template is available from the ethics committee web site. 
9.3 Patient recruiting 
Researcher worked in the clinic mainly in the office hours. Identifying inclusion criteria 
meeting patients was completed in co-operation with the clinic pharmacist and nurses. 
Potential research patients were observed through all patients receiving a treatment on each 
day the clinic was open. Our aim was to identify all patients who met the inclusion criteria 
during the study period. Researcher was contacted after nurse or a clinic pharmacist had 
identified a potential research patient. Then researcher made a short interview to the patient to 
confirm that patient met the inclusion criteria. Patient who met the inclusion criteria was 
given a brief verbal introduction of the study. Patient was allowed to familiarize with the 
patient fact sheet. Patient was allowed to ask questions after reading the fact sheet. All 
questions were answered. Agreement form was filled together with the patient if the patient 
was willing to participate in the study. Once agreement form was filled, the patient signed the 
form and thus researcher was allowed to study patient’s medical history. Agreement forms 
contained personal information thus they were contained in a locked locker in the clinic until 
the study ended. Patients were encoded in all other documents to protect their privacy. 
Confidential information was archived according to hospital pharmacy instructions when the 
study was finished. 
9.4 Interview and medication reconciliation  
Researcher checked patient’s medical history from the electronic medical records before the 
patient interview. Researcher also recorded the available background information from the 
medical database before the interview. Patients were encoded in the interview form. Interview 
began with medication reconciliation to record the most accurate medication list for the 
patient. Interview form (Appendix 1) was utilized in all interviews. Data collected with each 
section of interview form are summarized in table 11.  
Original interview form of the hospital pharmacy was modulated for this study and the 
interview form was piloted with 5 patients. Patients were asked after the interview if the 
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questions were hard to understand or if there was a chance of misinterpretation. All patients in 
the pilot study reported questions to be understandable and did not notice a chance for 
misinterpretation. These five patients were included in the final data. 
Table 10. Summary of contents in the interview form and aim of each section. 
Section Aim of the section 
Patient information To collect patient’s background information 
eg. diagnose, glomerular filtration rate, 
bloodpressure, heartbeat (were recorded from 
patient database) 
Medication Detect medications used on regular and per 
needed basis, vitamins and natural remedies 
Detect doses and dosing times 
Assistance questions for medications Detect medications that patients rarely report 
or consider as medications 
Pain management Detect problems in pain management 
To assess pain intensity with visual analogue 
scale (VAS) in the time of interview and 
fluctuation of pain intensity during the day 
Problems in medication use Detect problems in medication use, eg. 
problems in swallowing or opening packages 
Symptoms Detect possible medication related side 
effects 
Adherence to pain medication Determine level of adherence to pain 
medication and detect possible barriers to 
adherence 
 
Patient’s medication was gone over together with the patient in the interview and researcher 
recorded all deviations in the medication and included these in to the final report for the 
caring physician. Interview form included assisting questions to map drugs that patient would 
consider as medicines, such as medical patches or natural remedies. 
Interview form included questions on symptoms that are frequently associated with side 
effects of widely used medications. All symptoms were systematically asked if not visibly 
detectable. Symptoms are listed in the interview form appendix 1. 
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Interview form included questions on pain intensity and its variation during the day. Pain 
intensity was measured with visual analogue scale (VAS) on a separate sheet of paper. 
Fluctuation of pain intensity during a certain time of the day, for instance in the evenings, and 
probable reasons were assessed. If there was fluctuation in the pain intensity patient was 
asked to estimate the average intensity of pain on its worst in VAS. The time of taking pain 
medications was asked to determine its possible relation to the pain fluctuation. Patients were 
asked if they were satisfied with their pain management but also if there was anything they 
would change in their medication regarding the pain management. 
Adherence to pain medication was measured by enquiring medication taking behavior with 
Morisky 4-step adherence assessment scale (MMAS-4), presented in interview form, 
appendix 1. Answering yes to any question produced one point on the scale with maximum 
score of 4. Score 0 indicates for good adherence, 1-2 for moderate adherence and 3-4 for poor 
adherence. Patients were asked whether they had altered medication dosing without 
discussing the matter with caring physician. Patients were asked if they used their regularly 
prescribed analgesics regularly or per needed basis. Patients were asked if they had concerns 
on addiction, side effects, or tolerance of analgesics. Patients were also asked if they thought 
analgesics to be expensive. The adequacy of the information concerning pain management 
and the disease and its management were asked from the patients. Patients were asked if they 
thought patient-physician relationship to be good. Questions are in more detail in appendix 1. 
9.5 Completing medication reviews 
Medication review was conducted after the interview. Medication safety check form 
(Appendix 2) was utilized to assist completing the medication review for each patient. Table 
11 presents what factors were taken into account in completing medication review and which 
databases were used to find the information.  
Final medication review was written on one sheet of paper. Review included patient’s revised 
medication, important laboratory values, potential clinically significant interactions, 
recommendations on medication doses, recommendations to stop or start some medications, 
recommendations for enhanced follow-up or monitoring of patient and other observations on 
patient’s medications or diseases. 
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Table 11. Summary of revised factors for the medication review with assistance of medication 
safety check form.  
Medication safety check form Reviewed Databases used 
Side effects Reported side effects were 
compared with potential side 
effects of used medications 
Duodecim-medication 
database 
Overlap Overlapping of medications 
from therapeutic groups 
Duodecim-medication 
database 
Interactions Potential drug-drug interactions SFINX-Pharao-database, 
Lexi-Interact -database 
Dose Appropriateness of dosages 
taking patient’s kidney function 
into account 
Duodecim-medication 
database, Renbase-database 
Dosing time Appropriateness of dosing time 
was evaluated 
Duodecim-medication 
database 
Drugs to avoid in the elderly Elderly patients were evaluated 
according to national guidelines 
Medications in the elderly -
database (Finnish medicines 
agency FIMEA) 
Adherence to medication Adherence was evaluated 
according to questions in the 
interview form 
Interview form, MMAS-4 
scale 
Risk medicines and their 
association with symptoms 
Risk drugs were evaluated for 
their probable association with 
related symptoms 
List of risk drugs 
Other important observations Other important observations 
were recorded on the interview 
form 
Observations of the 
researcher 
 
Medication reviews focused on pain management because the interview form was designed to 
collect the most information on pain and pain management. Also patients attending to the 
study were using opioids thus very probably suffering from pain and probably required 
attention to the pain management. 
Medication reviews were sent for a revision to a hospital pharmacist via e-mail. Sent 
documents did not contain any confidential information. All patients were entirely encoded at 
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this point and only researcher had access to the confidential information. Hospital pharmacist 
made recommendations to improve the medication review and researcher made a reply if 
necessary. Most of the suggestions were completed into the medication reviews. 
Presenting medication review to caring physician 
The caring physician was noted as fast as possible once the medications review was 
completed. Medication review, filled interview form and medication safety check form were 
gone through with the physician immediately when the physician had enough time. 
Unfortunately, the review was seldom gone over within one or two days after the interview 
but in some cases after seven days. Caring physicians were allowed to connect patient 
encoding and personal information. Medication review was gone through with the physician 
step by step and physician altered patient’s medication according to recommendations if 
considered clinically important. Potential clinically significant interactions were discussed 
with the physician and it was decided by the physician whether the interaction was clinically 
significant or not. 
9.6 Follow up study 
A follow up study was conducted two months after the last patient was interviewed. Follow-
up study was conducted to determine frequency of implemented recommendations of the 
medication reviews. Also probable effect of the implemented recommendations was evaluated 
regarding to patients’ pharmaceutical care issues. In the follow up study the researcher 
reviewed all research patients’ electronic medical records to figure out how many of the made 
recommendations were actually initiated. Two physicians were included to the follow up 
study to help in evaluation of initiated recommendations. Patients who had gynecologic 
cancer were discussed with a gynecologist and other research patients with an oncologist. If 
patient’s medication was altered according to any recommendation in the medication review it 
was evaluated with the physician. Effect of the initiated recommendation was evaluated if it 
was possible with the electronic medical records. The evaluable implemented 
recommendations were rated as beneficial, harm inducing or no change for the patient. 
9.7 Statistics 
Statistical analyses of the study were performed with IBM SPSS Statistics Version 21. 
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10. Results 
10.1 Background information 
There were 31 patients included to the study and they all met the inclusion criteria. No record 
was kept on the patients who declined to participate to the study but amount of declined 
patients was estimated to be less than 10. Background information of patients is presented in 
table 12. 
Table 12. Patient background information (n=31).  
Background information n 
Male 15 (48 %) 
Female 16 (52 %) 
Age  
Median (range) 60 (23-79) 
18-45 3 (10 %) 
46-65 18 (58 %) 
66-100 10 (32 %) 
Drugs  
Total, median (range) 17 (10-23) 
Regular, median (range) 11 (6-18) 
Per needed, median (range) 6 (3-11) 
Analgesics, median (range) 3 (1-6) 
Cancer type  
Bowel cancer 7 (23 %) 
Pancreatic cancer 5 (16 %) 
Lung cancer 5 (16 %) 
Prostate cancer 4 (13 %) 
Genital cancer 4 (13 %) 
Breast cancer 3 (10 %) 
Skin cancer 1 (3 %) 
Other 2 (7 %) 
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Out of 31 research patients 16 (52 %) were females and 15 (48 %) males. Median age was 60 
for all patients whereas median for males was 59 and median for females was 62. The 
youngest patient was 23-year-old and the oldest was 79-year-old. Age distribution is 
presented in table 12. Glomerular filtration rate (GFR) was recorded for all research patients 
and was averagely 88 ml/min. Only 4 patients had GFR < 60 ml/min. The most prevalent 
cancer type among research patients was bowel cancer which had been diagnosed for 7 (23 
%) patients. Pancreatic cancer and lung cancer were both diagnosed for 5 (16 %) patients, 
respectively. Cancer types are presented in more detail in table 13. 
10.2 Adherence to pain medication 
Rate of adherence to pain medication was assessed by using Morisky’s 4-step medication 
adherence scale (MMAS-4). Table 13 presents the distribution of the answers to the MMAS-4 
items. The most yes answers got the question whether patients sometimes stop taking their 
medication if they feel better with 11 yes answers. 
Table 13. Frequencies of results to the questions of MMAS-4 (n=31). 
Question Answered yes (n) Answered yes (%) 
1. Do you ever forget to take your medicine? 4 13 
2. Are you careless at times about taking your 
medicine? 
6 19 
3. When you feel betted do you sometimes 
stop taking your medicine? 
11 36 
4. Sometimes if you feel worse when you take 
the medicine, do you stop taking it? 
3 10 
 
Table 14. Frequencies of MMAS-4 results. 
Morisky scale result n % 
0 = good adherence 15 48 
1 = moderate adherence 9 29 
2 = moderate adherence 6 19 
3 = poor adherence 1 3 
4 = poor adherence 0 0 
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Good adherence to pain medication was noticed in 15 (48 %) patients and 15 (48 %) showed 
moderate adherence. Only one patient got result for poor adherence to pain medication. 
MMAS-4 results are presented in table 14. No correlation between rate of adherence and VAS 
score was detected. 
Table 15. Frequencies of patients who answered yes to assistance questions (n=31). 
Question n % (proportion of all patients) 
Do you feel that your patient-physician 
relationship is on a good level?  
28 90 
Do you take analgesics regularly? 27 87 
Do you feel that pain is assessed enough? 25 81 
Do you feel that you have enough 
information on your cancer disease? 
25 81 
Do you feel that you have enough 
information on pain management? 
23 74 
Do you have concerns on analgesic side 
effects? 
18 58 
Have you altered analgesic dose without 
discussing with your physician? 
11 35 
Do you have concerns that analgesic will 
not relieve pain? 
9 29 
Do you have concerns on analgesic 
addiction? 
8 26 
Have you taken more analgesics than 
your physician has prescribed? 
8 26 
Do analgesics limit your everyday 
activities? 
5 16 
Do you think that analgesics are too 
expensive? 
2 6 
 
Eight (26 %) patients had taken more analgesics than prescribed or instructed because of 
intense pain and 3 (9 %) patients had taken less analgesics than prescribed. Possible reasons 
for poor adherence were detected using assistance questions and frequencies of the answers to 
the questions are presented in table 15. Concerns on analgesic side effects were seen in 18 (58 
%) patients. Almost all, 28 (90 %), of the 31 patients reported to have a good patient-
physician relationship and 25 (81 %) patients told that the pain is assessed adequately. 
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10.3 Drug interactions 
In this study 104 potential interactions were detected which was median of 3 interactions per 
patient. 97 % (n=30) of the patients had potential interactions. Of all potential interactions 38 
(37 %) were pharmacokinetic and 66 (63 %) were pharmacodynamic. 51 (49 %) of the 
potential interactions were related with analgesics. 27 (53 %) of analgesic interactions were 
related with oxycodone. Interactions are presented in table 16. 
Clinically significant interactions were detected in 7 patients and there was in total 7 clinically 
significant interactions. There were 6 clinically significant analgesic interactions detected 
which is 12 % of potential analgesic interactions (n=51). Oxycodone was related in 27 
potential analgesic interactions. 
Table 16. Potential and clinically significant interactions. 
Interaction n % 
Pharmacodynamic 66 63 
Analgesic 51 49 
Pharmacokinetic 38 37 
Clinically significant 7 7 
Clinically significant 
analgesic related 
6 6 
All 104 100 
 
First patient with a clinically important interaction experienced sedation as the result of the 
interaction. Patient had high dose of oxycodone (160 mg / day), used 125 mg of pregabalin 
per day, regularly used metoclopramide and temazepam but also lorazepam and haloperidol as 
needed basis. Patient was visibly exhausted in the time of interview. The second patient with 
clinically important interaction also had increased sedation as an outcome of the interaction 
and used morphine (10 mg / day), oxazepam (45-60 mg / day), and temazepam (20 mg / day) 
on regular basis. However, the patient also had depression which may contribute fatigue. The 
third patient had ibandronate and calcium prescribed to be taken simultaneously in the 
morning which reduces absorption of the ibandronate and is of clinical importance in long-
term use. Patient was not aware of such interaction. The fourth patient had increased 
constipation as a result of the interaction. Patient used oxycodone/naloxone and rosuvastatin 
but also received docetaxel and palonosetron with regular intervals which all induce 
constipation. The fifth patient used oxycodone 40 mg / day and bisoprolol 5 mg / day which 
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were considered to interact resulting in orthostatic hypotension. This was also supported by 
patient who described to receive dizziness when standing up too quickly. The sixth patient 
used low dose oxycodone 10 mg / day and pantoprazole in regular use but also received 
oxaliplatin and ondansetron with regular intervals which caused increased constipation. 
Patient had a laxative in use but despite this suffered from constipation. However, patient’s 
tumor was located in rectum which may contribute sensation of constipation. The last patient 
with clinically important interaction suffered from sedation and dizziness as the result of drug 
combination. Patient used levomepromazin 200 mg / day, pregabalin 300 mg / day, 
nortriptylin 50 mg / day, oxycodone 70 mg / day and venlafaxine 225 mg / day on regular 
basis and diazepam as needed. Patient had difficult psychological disorders that require strong 
and complex medications thus the medication is difficult to adjust for less sedative level. In 
the follow-up study it was detected that the patient had collapsed which was very probably 
contributed by the strong medication. 
10.4 Medication reviews 
Medication reviews were completed to all patients who attended the study. Researcher made 
in total 117 recommendations to the physicians which were made to 29 (92 %) patients. Table 
17 presents types of recommendations to the physicians. The most prevalent recommendation 
was enhancing patient follow-up with 22 (19 %) suggestions. The second prevalent 
suggestion was discontinuation of a medication with 12 (11 %) suggestions. 
Out of 117 recommendations 21 (18 %) were implemented in practice by the physicians after 
receiving medication reviews and were carried out in 13 patients. Effect of the implemented 
recommendations was evaluable in 10 patients of whom 7 patients received benefit (eg. lower 
cost, improved pain management, decreased side effects or symptoms) of the implemented 
recommendations in their pharmaceutical care issues. For remaining three patients the 
situation of the medication remained as it was before the medication review. In three patients 
implemented recommendations were not evaluable with electronic medical records. None of 
the recommendations hindered patients’ medication related problems. 
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Table 17. Recommendations presented to the physicians. Dose increase and dose decrease do 
not include analgesic dose altering. 
Recommendation n recommended 
(%) 
n initiated (% of same type of 
recommendation) 
Enhanced follow-up 24 (21) 3 (13) 
Discontinuation of medication 12 (10) 1 (8) 
Dose decrease 11 (9) 1 (9) 
Adding a medication 10 (9) 2 (20) 
Dose increase 9 (8) 3 (33) 
Adding an analgesic 9 (8) 1 (11) 
Analgesic switch 9 (8) 2 (22) 
Assessment of appropriateness 8 (7) 1 (13) 
Other 8 (7) 1 (13) 
Analgesic dose increase 7 (6) 3 (43) 
Switching to other medicine in 
same therapy group 
7 (6) 0 (0) 
Switching to cheaper medicine 2 (2) 2 (100) 
Analgesic dose decrease 1 (1) 0 (0) 
Total 117 (100) 21 (18) 
 
10.5 Analgesics 
All research patients were prescribed an opioid for pain management since it was one of the 
inclusion criteria. 31 research patients used all together 105 pain medications which of 63 
(60%) were opioids. Patients had 52 regular (50%) and 53 per needed (50%) pain medications 
in use. Pain medication median was 3 per patient. 
Frequencies and percentages of regularly prescribed analgesics are presented in table 16. 
Oxycodone was excessively the most used pain medication and was used by 27 (87 %) 
patients. Sixteen (52 %) patients used oxycodone as a regular drug and 25 (81 %) patients 
used oxycodone as needed basis. Three (10 %) patients were prescribed fentanyl for as needed 
basis. Paracetamol was used as needed by 12 (39 %) patients. NSAIDs were used by 11 (36 
%) patients as needed basis. 
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Table 18. Frequencies of regularly prescribed pain medications (n=31).  
Drug n (patients) % (patients) 
Oxycodone 16 52 
Paracetamol 8 26 
Oxycodone and naloxone 7 23 
NSAID 5 16 
Pregabalin 4 13 
Fentanyl 3 10 
Morphine 2 7 
Tramadol 2 7 
Codeine and paracetamol 2 7 
Nortriptyline 1 4 
 
10.6 Pain intensity 
VAS scores were rounded into full numbers. Patient recorded VAS score median during the 
interview was 1.5. Frequencies of reported pain intensities are presented in table 19. 
Thirteen (42 %) patients reported that there was no alteration in their pain correlating to a 
certain time of the day. 10 (32 %) patients told that they suffer from the worst pain in the 
evening. Four (13 %) patients reported having worst pain in the night time and 3 (10 %) 
patients told that the pain was worst during the daytime. The median VAS score for those 
who reported alteration was 4.0 in the worst time of the day. Frequencies of pain intensity of 
patients who reported fluctuation are presented in table 19. 
Table 19. Distribution of pain intensity at the time of interview and the worst pain for those 
patients who reported alteration during a certain time of the day. 
 Pain intensity (VAS 
score) 
n % of all patients 
All patients No pain (0) 8 26 
Mild pain (1-3) 17 55 
Moderate pain (4-6) 4 13 
Severe pain (7-10) 2 7 
Patients who 
reported pain 
fluctuation 
Mild pain (1-3) 2 7 
Moderate pain (4-6) 7 23 
Severe pain (7-10) 9 29 
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10.7 Medications 
Median drug amount per patient was 17. Median for regular medications was 11 and 6 for as 
needed medications. Median of pain medications per patient was 3. Maximum amount of 
medications per patient was 23 and minimum was 10. Anticonvulsants and antidepressants for 
analgesic purposes were included in the pain medications. 
The youngest age group (18-44 -year-old) had highest drug amount average of 23. The same 
group also had the highest average of regular, per needed and pain medications. Table 20 
presents more exact information on medication distribution between age groups. 
Table 20. Medication use in different age groups as medians. 
Age between Total Regular Per needed Pain 
medications 
18-44 23 15 8 5 
45-64 16 10 6 3 
65- 17.5 10.5 6.5 3 
 
All medications that patients reported to use are presented in table 15. All patients had a 
medication affecting alimentary tract as well as anticancer therapy since it was in the 
inclusion criteria.  26 (84 %) patients had a therapy for constipation. 25 (81 %) patients had 
metoclopramide as a prescribed drug but 18 (58 %) patients had been prescribed an actual 
antiemetic. Systemic hormone was used by 29 (91%) patients which was in most cases 
dexamethasone. Heart and coronary disease related medications were used by 19 (61 %) 
patients. When opioids were excluded, central nervous system affecting drugs were used by 
19 (61 %) patients that consisted mostly of sleeping pills. Nine (29 %) patients used an 
antidepressant for treatment of depression. Median for anticancer therapies per patient was 2. 
Overlapping of the used medications were recorded if two or more drugs from the same 
therapeutic group were used and 12 (39 %) patients had 2 drugs from the same therapeutic 
group and 2 (7 %) patients had 3 drugs from the same therapeutic group without a clear 
indication. 
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Table 21. Frequencies of patient used medications, excluding analgesics (n=31). 
Medication n (patients) %  (patients) n (medications) 
Alimentary tract and 
metabolism 
31 100 174 
  Hyperacidity 28 90 31 
  Metoclopramide 25 81 25 
  Antiemetics 18 58 22 
  Drug for constipation 26 84 43  
  Antidiabetics 6 19 9 
Blood and blood 
forming organs 
13 42 18 
Cardiovascular system 19 61 37 
Genito urinary system 
and sex hormones 
8 26 8 
Other systemic 
hormones 
29 94 41 
Systemic antiinfectives 3 10 3 
Antineoplastics and 
immunomodulators 
31 100 69 
Musculoskeletal system 
(not NSAIDs) 
10 32 10 
Central nervous system 
(not opioids) 
19 61 40 
  Sleeping pill 18 58 26 
  Benzodiazepine deriv. 13 42 18 
  Antidepressants (not     
amitriptyline or 
nortriptyline) 
9 29 9 
Respiratory system 10 32 16 
Sensory organs 3 10 3 
Various 3 10 4 
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10.8 Side effects 
Frequencies of the symptoms reported by the patients during the interview are presented in 
table 17. The most prevalent symptom was pain in 81 % of the patients. The next prevalent 
symptoms were dry mouth in 23 (74 %) and sweating in 20 (65 %) patients. Sleep disorders, 
nausea and anxiety were reported by 19 (61 %) patients, respectively. Dizziness and fatigue 
were reported by 18 (58 %) patients, respectively. Constipation was reported by 16 (52 %) 
patients. 
Table 22. Frequencies of symptoms reported by patients (n=31). 
Symptom n % 
Pain 25 81 
Dry mouth 23 74 
Sweating 20 65 
Sleep disorders 19 61 
Nausea 19 61 
Anxiety 19 61 
Fatigue 18 58 
Dizziness 18 58 
Constipation 16 52 
Heartburn 14 45 
Urinary difficulties 12 39 
Itching 12 39 
Shortness of breath 12 39 
Swelling 11 36 
Arrhythmias 8 26 
Cramps or pain in legs 8 26 
Chest pain 6 19 
Cough 4 13 
Falls 4 13 
Visual disturbance 3 10 
Diarrhea 2 7 
Amnesia 1 3 
Disorientation 1 3 
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12. Discussion 
 
Before the study we hypothesized that some patients would not use their analgesics as 
instructed. This was partly true because third of the patients intentionally stopped taking their 
analgesics at occasion. Medication adherence assessment showed that almost all patients were 
either well or moderately adhered to their pain medications. This does not entirely respond to 
the hypothesis. In our knowledge this research was the first to study adherence to pain 
medications in cancer patients. Clinically important interactions were presumed to be rare. 
Only a few clinically important interactions were detected and they were unmanageable. 
Recommendations of the pharmacist completed medication reviews were poorly accepted in 
planning of pharmaceutical care. In our knowledge this was the first study to evaluate the 
effect of pharmacist collated medication reviews on patients’ pharmaceutical care issues in 
Finland. Pharmacist completed medication reviews show potential in reducing patients’ 
medication related problems 
12.1 Background information 
We determined to interview only 30-40 patients which was considered to be appropriate 
sample for a master’s thesis. A bigger proportion of patients would have produced more 
reliable results yet the workload would have increased too heavily for a master’s thesis. Only 
31 patients were interviewed for the study because inclusion criteria meeting patients were 
less frequent than expected. Also some patients declined to participate to the study which also 
decreased the sample size. On some days there were too many potential research patients thus 
researcher simply did not have enough time to interview all patients or patient had left before 
interview could have been conducted. 
Inclusion criteria were successful by determining that patient uses a regular opioid because 
our primary aim was to study adherence to regular analgesics. However, determining 6 
regular drugs was not necessary due to interactions because 5 drugs have shown to be enough 
to increase the risk for drug interactions (Nikolic et al. 2014). Inclusion criteria well 
determined patients to be in active anticancer therapy which succeeded in regard that no drug 
interactions between anticancer drugs and other drugs were detected. Patients remembered 
their own medications well in the interviews probably because we decided to include only 
patients who took care of their own medicines. However, this excluded many patients 
receiving dosing help from relatives or a pharmacy. 
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Gender distribution in this study was slightly different from the incidence of cancer in general 
in Finland where men are diagnosed with cancer slightly more often and in our study there 
were slightly more females (Engholm et al. 2013). Patients median age was 60 which was 
expected since older patients receive help with their medication and were excluded from the 
study. Also the incidence of cancer increases with age thus not many young patients were 
expected to be included to the study. Median amount of drugs used was 17 which is higher 
than expected because most of the patients were of working age and relatively healthy if the 
cancer was excluded. This is probably a result from our inclusion criteria of six regular drugs. 
The median for regular drugs was 11. However, regular drugs included the anticancer 
therapies and median of anticancer drugs was two per patient. Interestingly the youngest 
patients had the most drugs in use and 3 patients aged between 18-44 years old had median of 
23 of drugs in use. There is no single factor that can explain this result, however, these 
patients were diagnosed with poor prognosis which may induce use of symptom relieving 
drugs (Managing symptoms of a dying patient [Kuolevan potilaan oireiden hoito]: Käypä 
hoito recommendation 2012). 
12.2 Adherence to pain medication 
48 % of research patients were well adhered to around-the-clock pain medication when 
MMAS-4 was used as a single measure. The result is distinct from Miaskowski’s and 
Valeberg and colleagues’ results (Miaskowski et al 2001, Valeberg et al. 2008). Miaskowski 
and colleagues showed that even 84.5 – 90.8 % of outpatients (n=65) using around-the-clock 
opioids were highly adhered to their pain medication (Miaskowski et al. 2001). Valeberg 
showed that only 21 % of the cancer patients (n=174) with pain were well adhered to their 
pain medications when all analgesics were considered (Valeberg et al. 2008). However, 
Valeberg et al. and Miaskowski used distinct adherence assessment measure than we did 
(Miaskowski et al. 2001, Valeberg et al. 2008). The rate for adherence in this study is 
however similar with Morisky’s study in hypertensive patients (n=290) of whom 43 % were 
highly adhered to their long-term medication which was measured with the same method than 
we did (Morisky et al. 1986). 
29 % of the patients scored 1 in MMAS-4 which indicates for moderate adherence, 19 % of 
the patients scored 2 and only 1 patient scored 3 in MMAS-4 indicating poor adherence. 
These results are similar compared to Morisky and colleagues’ study in other aspects but 9 % 
of the patients scored 4 in their study and in our there were none (Morisky et al. 1986). 
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However, this is not consistent with Valeberg and colleagues’ study where it was shown that 
up to 46 % of the patients were nonadherent to their pain medications (Valeberg et al. 2008). 
Surprisingly, 36 % of the patients reported to stop taking the analgesics if they felt better 
which indicates for intentional deviation in adherence. Only a small proportion, 13 % of 
patients forgot at times to take their analgesics and 19 % reported to be careless at times in 
administrating their medications. 10 % of the patients reported to stop taking their pain 
medication if they felt worse after administrating the medicine. This indicates that deviations 
from the instructions in taking the medicines are due to intentional nonadherence rather than 
unintentional. This result was according to the hypothesis made by the chief physician for the 
study. Chief physician also thought that if patients stop taking the analgesic when they feel 
better, may result in sudden pain and seek for medical attention in emergency department. 
This has been documented to increase health care costs (Graziottin 2011). 
35 % of the patients had altered analgesic dose on their own without discussing it with the 
physician and 29 % had taken more analgesics than prescribed due to intense pain. This may 
indicate that the patients taking more analgesics are undertreated in respect to their pain. 
Percentage is lower when compared to Deandrea and colleagues’ result that 43 % of oncology 
patients who experience pain are undertreated in respect to their pain (Deandrea et al. 2008). 
These questions were not included in the MMAS-4 which may indicate that adherence to pain 
medications is actually lower. In addition, it is known that self-report questionnaire may 
overestimate medication adherence which may have produced higher results in MMAS-4 in 
our study (Lehmann et al. 2014). 
13 % of the patients self-reported using analgesics only per needed even though prescribed to 
be used regularly. There was statistically significant correlation (p < 0.05) between patients 
using analgesics per needed and VAS score at the time of the interview. This indicates that 
patients who did not use their medications according to physician’s instructions resulted in 
more intense pain. This could be overcome by educating patients of the importance of 
regularity of the ATC analgesics. Patient education has been shown to decrease intensity of 
pain and also shown some increase in adherence to analgesics if given correctly which could 
benefit patients in our study population (de Writ et al. 1997, Bennett et al. 2009, Oldenmenger 
et al. 2011). 26 % of the patients in the study reported having inadequate information on pain 
management which led to the fact that a few patients did not entirely know that modified-
release analgesics are designed to be used regularly. 
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Barriers 
The questions to assess barriers to pain medications were chosen by their probable effect on 
medication adherence according to Graziottin and colleagues’ study (Graziottin et al. 2011). 
Highest prevalence, 58 %, for a barrier was the concern of analgesic induced side effects 
which was less frequent than in Potter and colleagues’ study where they showed that 71 % of 
the patients (n=93) with malignancy had fear for analgesic induced side effects (Potter et al. 
2003). The second most prevalent barrier was fear for tolerance with prevalence of 29 % 
whereas Potter et al. showed that 55 % of the patients with malignancy had fear for tolerance 
of analgesics. 26 % of the patients had fear for addiction which compared to Potter and 
colleagues’ study is nearly three-fold less as they showed fear for addiction in 75 % of their 
study patients. Significantly lower frequencies in our study may be a result from that our 
patients were already prescribed an opioid regimen for pain which indicates that information 
concerning analgesics and pain management has been given at physician appointment. Also 
this may be due to successful pain management in the Kuopio University hospital cancer 
clinic since adequate pain management has been shown to be related to fewer barriers to pain 
management (Oldenmenger et al. 2009). 
Patients who stated having concerns of analgesic side effects were more likely to score higher 
in VAS both at the time of interview and  the worst pain during the day (p < 0.05). This is 
aligned with the results from Ward and colleagues’ study where they showed that patients 
(n=270) with more concerns on analgesic side effects were more likely to be undertreated in 
respect to their cancer related pain (Ward et al. 1993). However, there was no statistically 
significant correlation between any assessed barriers and MMAS-4 score. A large portion of 
patients in this study had concerns on analgesic side effects which may partly explain why 
patients stop taking pain medication if they feel better but no statistical correlation was 
noticed. Also patients in our study had concerns on addiction and tolerance which may 
similarly decrease adherence to pain management regimen and affect success of pain 
management. However, no correlations to any other factors were detected. 
12.3 Drug interactions 
We detected 104 potential interactions which of 37 % were pharmacokinetic and 63 % were 
pharmacodynamic. All clinically important interactions were pharmacodynamic interactions. 
Potential interactions occurred in 97 % of the patients which is significantly higher than 
prevalence suggested by Riechelmann and Del Giglio who showed prevalence for drug 
interactions in 12-63 % of the oncology patients in their review (Riechelmann & Del Giglio 
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2009). However, in the same review it was not determined how many drugs patients used 
whereas our study made clear criteria for amount of drugs in use in research patients which 
probably affected our result. Threshold for increased risk for potential clinically significant 
interactions has been shown to be 5 or more regularly used drugs (Nikolic et al. 2014). 51 % 
of the detected potential interactions were associated with the analgesics which is very 
probably associated with our inclusion criteria that the research patient should use or be 
prescribed an around-the-clock opioid medication. Nevertheless, we detected only 7 clinically 
important interactions which of 6 were associated with analgesic regimen. There was a 
statistically significant correlation between amount of all medications used and amount of 
potential drug interactions (p < 0.05) which was expected (Köhler et al. 2000). However, 
prevalence of analgesic interactions is less documented and no comparable study was found 
for this study. In total, 7 patients had a clinically important interaction which is after all 23 % 
of research patients that is relatively large proportion. Altogether, this indicates that clinically 
significant drug interactions are quite rare in oncology outpatients who use opioids. 
High proportion of pharmacodynamic interactions may be a result from inadequacy of 
national interaction detection program SFINX-PHARAO which does not warn of 
pharmacodynamics interactions. However, the program shows a risk for some 
pharmacodynamic interactions which is a relatively new feature in the program and may not 
be well known among physicians. Interactions associated with the analgesics were 
pharmacodynamic interactions as it was assumed due to frequent sedative and constipation 
inducing adverse effects of opioids and high frequency of used CNS depressants. Mechanism 
of sedative interactions is established (Jann et al. 2014) but it remains unclear whether 
constipation actually is an interaction or the sum of adverse effects. There was a statistical 
correlation (p < 0.05) between amount of CNS depressants used and amount of potential 
interactions, potential analgesic interactions and potential pharmacodynamic interactions. 
Clinically important interactions detected in the study were mostly unmanageable due to 
necessity of the drugs in use. Thus it is difficult to withdraw any of the interactive 
medications without adequate assessment and follow-up. Also, most of the clinically 
important interactions were associated with the analgesics which are necessary to maintain the 
quality of patient’s life. 
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12.4 Medication reviews 
Medication reviews were completed to all patients attending the study. Most of the 
recommendations in the medication reviews concerned enhanced follow up mostly for 
potential medication induce adverse effects such as hemoglobin measuring if patient used 
NSAIDs on regular basis. Analgesics were frequently recommended to add or increase 
analgesic dose due to nonadherence to pain management guidelines or probable under-
treatment of patient’s pain. 
Recommendations for medications were made for 92 % of all patients in total 117 
recommendations. Only 21 (18 %) recommendations were carried out in practice which is 
surprisingly low proportion.  Percentage is lower compared to 28 % of implemented 
recommendations in Valkonen’s master’s thesis (n=25) which was conducted in an inpatient 
ward in Kuopio University hospital (Valkonen 2014). However, in different settings 47 - 90 
% of pharmacist made recommendations have been implemented by the physicians 
internationally which also are significantly higher than the result in this study (Zermansky et 
al. 2006, Christensen et al. 2011, Perera et al. 2011, Bondesson et al. 2012, Bondesson et al. 
2013).  
Low rate for implemented recommendations may be partly a result from inexperience of the 
researcher (pharmacy student) made medication reviews thus all recommendations may not 
have been of clinical importance. For example, paracetamol was recommended to be initiated 
for regular use to all of the first five patients of the study even though there may be a risk that 
paracetamol may conceal symptoms of an acute infection (Kristiina Koskela, verbal 
information 6.11.2014). Thus paracetamol was not initiated as regular analgesic to any 
patient. In addition, all medication related problems may not be of clinical importance in 
patients with cancer since cancer treatment requires medications despite their adverse effects. 
Also medications may be used to manage symptoms that are more disturbing than medication 
induced adverse effects. In some cases the caring physician agreed with the researcher of 
many recommendations and intended to implement the recommendations but when the follow 
up study was conducted implementations could not be detected. This may be a result from the 
busy work of the physicians and thus they may not remember the received medication review. 
Clinical pharmacists are not a customary profession in hospital environment in Finland and 
physicians may not entirely trust pharmacists’ expertise. However, detecting some of the 
implemented recommendations was difficult such as enhanced follow up or giving medication 
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information since they are rarely noted in the medical records which may end up in lower 
implementing rate than it actually was. 
Recommendations were implemented in 13 (42 %) patients and were evaluable in 10 patients 
with electronic medical records. Implemented recommendations in the remaining three 
patients were not evaluable because there was no sign of assessment of implemented 
recommendation in the patients’ medical records. Seven of the patients received benefit from 
the implemented recommendations regarding their pharmaceutical care issues such as 
improved pain management, reduced symptoms or side effects or reduced medication cost. 
Quality of the benefit was not further assessed. Thus 54 % of the patients who were 
implemented medication review based recommendations benefitted from the medication 
reviews. Gagnon and colleagues showed in their study that clinical pharmacist performed 
assessment to outpatients in a radiotherapy outpatient clinic improved patients’ medication 
related problems and 80 - 98 % of the patients received relief in symptoms such as fatigue and 
drowsiness (Gagnon et al. 2011). Including a clinical pharmacist in a multidisciplinary team 
has reduced frequency of unidentified medication related problems (Bondesson et al. 2013). 
However, Holland et al. showed in their review that pharmacist-led medication reviews do not 
significantly reduce deaths or hospital admission in the elderly (Holland et al. 2007). There is 
controversial evidence whether pharmacist collated medication reviews are cost-effective 
since there is only seen slight reduce in prescribing medicines but no reduce in hospital 
admissions (Holland et al. 2007, Desborough et al. 2012). Thus it can be concluded that 
pharmacist completed medication reviews show potential in improving patient pharmaceutical 
care issues. 
A better approach to evaluation of implemented recommendations or efficacy of the 
medication reviews would have been patient interviews. However, this was not possible 
because the research patients were told before they agreed to attend the study that there would 
be no extra interviews apart from the planned interview. 
12.5 Analgesics and pain intensity 
Pain intensity 
Median VAS score was 1.5 which indicates that in general pain management is successful and 
adequate in the outpatient clinic since pain is considered adequately managed when VAS 
score is < 3 (Kalso 2013 pp. 887). 26 % of the patients reported no pain and 55 % of the 
patients scored 1-3 in VAS scale which indicates that 81 % of the research patients were 
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adequately managed regarding to their pain. However, all patients in the clinic were not 
included in the study because only patients taking opioids met the inclusion criteria. This may 
partly explain why pain management is on such a good level compared to international studies 
(Deandrea et al. 2008). Deandrea and colleagues showed in their review that up to 43 % of the 
oncology patients who suffer from cancer related pain are undertreated in respect to their pain. 
In addition, Breivik and colleagues showed in their study that only 11 % of the Finnish 
patients who suffer from moderate to severe pain use strong opioid drug regimen for their 
pain which may indicate that there are plenty of patients outside our inclusion criteria who 
suffer from moderate to severe pain (Breivik et al. 2009). Initiation of opioid regimen, 
however, indicates that pain is being managed and may thus explain our results of low VAS 
scores in the study population. 
Opioids 
All patients had an ATC opioid either in use or prescribed for regular use. Oxycodone was the 
most used opioid in this study and was used by 87 % of the patients. Morphine is suggested to 
be the first line strong opioid for patients with cancer pain (WHO 1996, Kalso 2013). There is 
limited evidence to support the superiority of oxycodone compared to morphine as an 
analgesic (Olkkola et al. 2013). Nevertheless, some studies have shown that oxycodone 
induces less hallucinations and less nausea which may partly explain its high use also in 
cancer patients (Olkkola et al. 2013). Thus it is surprising that only one patient took morphine 
per orally in this study and one had subcutaneous infusion of morphine. This also indicates 
that the outpatient clinic does not manage pain according to available guidelines. 
Oxycodone/naloxone combination was used by seven patients which is relatively low 
prevalence in respect to high incidence of constipation. Low use may be due to high price and 
lack of reimbursement of the combination product in Finland. Fentanyl was regularly used by 
three patients which indicates that the pain is primarily treated with per orally administered 
opioids according to recommendations in the guidelines (WHO 1996). However, fentanyl 
could provide benefit in some patients due to its less frequently induced constipation (Kalso 
2009 pp. 494, Wiffen et al. 2013). Two patients were prescribed tramadol and one patient was 
prescribed codeine combined with paracetamol which indicates that patients are frequently 
prescribed a strong opioid for cancer pain.  
NSAIDs and paracetamol 
Paracetamol was used regularly by 26 % of the patients whereas an NSAID was used by 16 % 
of the patients. This finding is distinct from the WHO guideline where an opioid is suggested 
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to be added to a non-opioid regimen (WHO 1996, Kalso 2013 pp. 884). In addition, 
paracetamol and NSAIDs were used per needed basis in 39 % and 36 %, respectively, which 
emerges even more concern in respect to following the guidelines in the clinic. However, in 
practice paracetamol is seldom used for regular basis because it may hide symptoms of an 
infection (Kristiina Koskela, verbal information 6.11.2014). Some studies have challenged the 
benefit of using paracetamol concurrently with strong opioids in oncology patients which may 
also partly explain the low use of paracetamol in the clinic (Axelsson et al. 2008). Low 
frequency of regularly used NSAIDs is probably due to their potential side effects (Non-
steroidal anti-inflammatory drugs: Käypä hoito –recommendation 2009). 
Pain intensity alteration during the day 
Patients were assessed concerning fluctuation of the pay during a certain time of day but 
actual breakthrough pain was not assessed. If patient said that the time for most intense pain 
could not be defined patient was automatically considered not having pain fluctuation. 58 % 
of the patients were able to define fluctuation in pain intensity during a certain time of the 
day. 32 % of the patients reported that they suffer the most intense pain in the evening. Many 
patients believed that fluctuation may be a result from physical distress but few patients also 
reported that staying still and being inactive concentrated their thoughts on pain. Patients were 
asked to estimate intensity of pain in the most intense time of the day and surprisingly 29 % 
of all patients reported severe pain and 23 % reported moderate pain at some time of the day. 
This may indicate that drugs for breakthrough pain are not adequately prescribed or used. 52 
% of the patients suffer from pain > 3 in the VAS scale at some point of the day which 
indicates that pain management may not be adequate in all patients.  
However, breakthrough pain is difficult to manage due to required high doses of opioids 
which may induce more side effects (Mercadante 2014). In addition, breakthrough pain is 
frequent and is present in 59 % of the cancer patients (Deandrea et al. 2014) which indicate 
that breakthrough pain may momentarily increase VAS score. However, patients were not 
assessed for efficacy of their breakthrough pain medications thus it may not be concluded 
whether management of breakthrough pain is inadequate.  
Only 10 % of the patients were prescribed fentanyl for as needed basis. Fentanyl has shown 
the highest efficacy in management of breakthrough cancer pain (Zeppetella & Davies 2013) 
which might provide some benefit for the patients in the clinic who suffer from breakthrough 
pain. 81 % of the patients were prescribed oxycodone to be used as needed which may be a 
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result from misbelief that the same opioid should be used for breakthrough pain as it is used 
for ATC opioid (Zeppetella & Davies 2013). Zeppetella & Davies showed in their review that 
studies available do not support this practice and fentanyl pain has been used with high 
efficacy with other ATC opioids for breakthrough pain (Zeppetella & Davies 2013). Yet, 
mucosal fentanyl products are very expensive which may partly explain low frequency of 
their use in the clinic. Only one patient did not have any prescribed analgesic to be used as 
needed due to continuous subcutaneous infusion which can be used to inject additional 
injections if needed. Even though patients were prescribed analgesics as needed basis, all of 
the patients did not use them. Some patients did not use as needed analgesics due to lack of 
breakthrough pain but few patients were afraid of side effects and few patients considered 
analgesics to be used as the last option for the pain. However, this study mainly aimed to 
study adherence to regularly used analgesics instead of as needed used. 
Such a big proportion reporting the most intense pain in the evening may indicate that 
analgesic dosing should be adjusted to allocate the most effective analgesia for the evening 
time for some patients. 13 % of the patients in our study reported to have the most intense 
pain in the night time which indicates requirement for a stronger dose of the ATC analgesic in 
the evening. In this study we could not detect that pain fluctuation correlated to inadequeate 
dosing of the analgesics. 
Adjuvant analgesics 
In our study four (13 %) patients used pregabalin and one (3 %) patient used nortriptyline for 
neuropathic pain. In addition one patient used tramadol for neuropathic pain. The result is 
consistent with Bennett and colleagues’ study where they showed that 20 % of the patients 
suffer from neuropathic pain (Bennett et al. 2012). However, our study population is not 
entirely comparable since we only included patients with opioids in our study. Bennett et al. 
suggested that prevalence of mixed type of cancer neuropathic pain reaches up to 40 % of the 
patients which is significantly higher than our result. Pregabalin being the most used 
medication for neuropathic pain in this sample is supported by the study conducted by Mishra 
et al. who suggested that pregabalin is the most effective drug for cancer related neuropathic 
pain (Mishra et al. 2012). However, our sample is small to detect reliable results for 
prevalence of drugs used for cancer related neuropathic pain. 
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12.6 Other medications 
All patients had alimentary tract and metabolism affecting drugs which was expected because 
medications that are frequently used to manage anticancer therapy induced nausea were 
included in this group (Elonen & Bono 2013 pp. 182-185). Metoclopramide is used to treat 
nausea and 81 % of patients in this study had metoclopramide in use mostly for as needed 
basis. The number is still high in respect to metoclopramide frequently induced side effects, 
such as sedation and weakness (Duodecim-medication database 2015). Actual antiemetics 
(aprepitant, palonosetron, ondansetron) were used only by 58 % of the patients which is lower 
percentage than expected because all patients included in the study were at the time of 
interview receiving active anticancer therapy. However, all anticancer therapies are not highly 
emetic and thus antiemetics may not be required with all therapy regimen (Elonen & Bono 
2013 pp. 182-185). In addition, antiemetics are not always adequately recorded in the 
electronic medical records and may have been undetected. 
84 % of the patients attending the study were prescribed medications to treat constipation but 
are recommended to all patients who receive long term opioid therapy (Davies 2009 pp. 357). 
90 % of the patients used a drug to treat hyperacidity mostly for unknown reasons. Some 
patients indeed used an NSAID or some other medication that may induce disturbance in the 
stomach but the high percentage remains unexplained. Some patients reported to use 
hyperacidity alleviating drugs for stomach protection which may in fact be caused by 
anticancer therapies and other drugs used, such as dexamethasone (Duodecim –medication 
database 2015). 94 % of the patients used some systemic hormone which was in almost every 
case dexamethasone which was prescribed for nausea prevention during anticancer therapy. 
61 % of the patients used some other CNS depressants than opioids which of 42 % used some 
regimen of benzodiazepines. Antidepressants were used by 29 % of the patients if TCAs were 
not included. Frequency of antidepressant use was expected due to cancer induced 
psychological distress (Jones 2001). 
12.7 Side effects 
Patients were asked if they experienced any medication induced side effects but nearly none 
of the patients reported having any. However, patients were assessed for symptoms that are 
probable side effects of commonly used drugs with assistance of the interview form. There 
was no control group in this study thus it is impossible to reliably compare whether side 
effects were caused by the medications or some other factors. 
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Opioids 
Our study found that if pain is excluded from symptoms dry mouth is the most prevalent 
patient reported symptom (74%) which is aligned with other studies (Palos 2008, Glare 2009 
pp. 132-134). Dry mouth is known side effect of opioids but infrequently reported by patients 
but it may affect oral hygiene. None of the patients reported to use any products as synthetic 
saliva for managing dry mouth which indicates that this symptom is not readily reported to 
the health care providers. 
In our study 52 % of the patients reported constipation which is aligned with studies that have 
reported frequency of 27-70 % for opioid induced constipation (Palos 2008, Glare 2009 pp. 
132-134) However, 84 % of the research patients also used one or more medications to 
manage constipation which arises an emerging fact that despite management patients suffer 
from constipation. Nevertheless, it was not measured how disturbing the constipation is thus it 
is not possible to draw any conclusions about efficacy of the agents used to manage 
constipation. All research patients used an opioid medication or were prescribed one but 16 % 
of the patients did not have a laxative to treat constipation which is distinct from the guideline 
recommendation (WHO 1996). 
Fatigue was highly prevalent in our patients and reported by 58 % of the patients which is 
consistent with studies on opioid induced side effects (Palos 2008, Glare 2009 pp. 132-134). 
Dizziness was also reported by 58 % of the patients. Dizziness is associated with higher risk 
for falls which may cause hospital admissions and fractures (Lönnroos 2009). Tolerance is 
frequently built up to sedative adverse effects may remain persistently if another CNS 
depressant is used concomitantly with opioids (Davis 2009 pp. 355). In our sample few 
patients had undergone dose increase recently before the interview which may partly explain 
high frequencies of dizziness and fatigue. In addition, 61 % of the patients used some other 
CNS depressant concurrently with the opioid which may induce persistent sedation. This 
strongly indicates that CNS depressants play some role in fatigue and dizziness experienced 
by cancer patients who use opioids. Also metoclopramide is capable of inducing sedation 
(Duodecim-medication database 2015) which also may contribute sedative properties of 
opioids. 
Sleeping disorder and anxiety were reported by 61 % of the patients, respectively. Opioids 
may induce disturbances in sleep disorders (Palos 2008). However, anxiety is frequently 
associated with cancer which also may cause sleep disturbances (Jones 2001) and thus anxiety 
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is more probable cause of sleep disturbances than opioids. It is improbable that these 
symptoms are induced by opioids.  
Sweating is a common side effect of opioids and was reported by 65 % of our research 
patients which is similar as reported in the literature (Glare 2009 pp. 132-134). However, 
sweating is frequently associated with anticancer therapies (Duodecim-medication database 
2015) thus it is impossible to conclude whether sweating is a result from opioids or anticancer 
therapies. 
61 % of the patients in our study reported nausea which is also a known side effect for 
opioids, however, with lower frequency (15-30 %) (Davies 2009 pp. 357). However, in this 
study nausea is more likely caused by anticancer therapies because they more frequently 
induce emesis compared to opioids (Elonen & Bono 2013 pp. 182-185). Itching is also a 
common side effect for opioids and was detected in 39 % of our research patients yet many 
other factors may induce itching such as dry skin or some anticancer therapies (Duodecim-
medication database 2015). 
One patient in the study declined to use ATC oxycodone due to its strong side effects which 
he claimed to be induced by oxycodone. Symptoms were, however, untypical for oxycodone 
such as joint pain and aching in the muscles. In addition, one patient who used codeine 
combination product did not want to use strong opioids because of fear for side effects despite 
patient had moderate pain especially in the evenings. 
It may be concluded that patients frequently suffer from opioid induced side effects also in 
this population. Yet, there are many other factors that may contribute high prevalence of these 
symptoms for example other medications such as anticancer therapies that also frequently 
induce side effects. 
NSAIDs 
Heart burn was seen in 45 % of the patients in our study which may be a symptom of NSAID 
induced adverse effect in respect to their GI tract irritating effect (Non-steroidal anti-
inflammatory drugs: Käypä hoito -recommendation 2009). However, most of the patients 
using NSAIDs in our study used them as per needed basis which rarely causes long-term heart 
burn (Ong et al. 2007). In this population heart burn was more likely caused by other drugs 
such as anticancer therapies and dexamethasone that are frequently associated with gastric 
adverse effects (Duodecim –medication database 2015). In addition, patients in the study very 
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frequently used protein pump inhibitors (PPI) which may decrease incidence of heart burn. 
Thus it cannot be concluded that patients in our study experienced NSAID induced adverse 
effects. NSAID induced gastric ulcers were undetectable in our study. Some patients had low 
hemoglobin values but could not be linked to NSAID use. 
12.8 Limitations 
Results of this study are limited by the small patient sample (n=31) which results in poor 
comparability to other studies and poor implication to the practice. Patient recruitment may 
have failed to recruit all patients during the research period. Clinic pharmacist and nurses may 
not have been able to detect all potential patients for the research due to other work they had. 
Thus our sample may be skew.  
Self-reported patient questionnaires may produce unreliable results due to unwillingness of 
the patients to answer truthfully for social approval. Questions concerning pain medication 
and adherence have not been validated for use in Finland thus the results may be unreliable. 
Morisky 4-step medication adherence measure (MMAS-4) was not validated to use before the 
study thus results concerning analgesic adherence are not entirely reliable.  
Visual analogue scale (VAS) has shown to be reliable in assessing intensity of pain but it may 
be more difficult to use in the elderly (Jensen 2003). Thus numerical rating scale (NRS) might 
have been easier to implement to use for pain intensity assessment. However, patients in this 
study did not have any difficulties in completing the measure probably due to help from the 
researcher if there was any hesitation. Brief pain inventory would probably have been better 
in assessing pain in this study due to its good validity but it would have lengthened the patient 
interview. 
Medication reviews were completed by a pharmacy student thus all recommendations in the 
reviews may not have been of clinical importance. This may have caused the low 
implementation rate for recommendations and may thus not be used in clinical practice. Also 
our results are not entirely comparable with other studies because medication reviews have 
mostly been completed by graduated pharmacists. Recording and evaluation of implemented 
recommendations with electronic medical records is not a reliable way to assess medication 
review due to incomplete recorded data in the medical records. 
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13. Conclusions 
Patients treated in the outpatient clinic of cancer center are generally well treated in respect to 
their pain but analgesics, especially opioids, frequently induce side effects. 
Patients are well or moderately adhered to their pain medications which rarely results in 
problems in pain management. Patients have fear for analgesic induced side effects and have 
other barriers to pain management. However, some patients are not aware of indication of 
regularly used analgesics and irregular use may result in increased pain. Adherence should be 
routinely assessed in the future to prevent problems in pain management. 
Clinically important interactions are rare in cancer patients but are likely to be related to 
analgesic regimen resulting in additive sedation or constipation. 
Physicians were not receptive to the recommendations considering pharmaceutical care due to 
unknown reasons. However, patients who were implemented recommendations did receive 
benefit regarding to their pharmaceutical care issues. Thus it can be concluded that pharmacist 
completed medication reviews show potential in providing beneficial assistance to patients’ 
medication related problems.  
What did we know before the study? 
Cancer pain management is not adequately managed in all patients. Adherence to analgesic 
regimen in cancer pain is not complete and may result in problems in pain management. 
Pharmacist conducted medication reviews show potential in reducing pharmaceutical care 
issues in other countries. 
What did this study add? 
This study showed that patients who already receive opioids are adequately managed 
regarding to their pain in outpatient setting. Adherence of patients with cancer pain who use 
opioids is good or at least moderate even though prejudices toward analgesics are frequent. 
Clinically important interactions are rare and rarely manageable due to necessity of 
medications in cancer patients who use opioids. Pharmacist conducted medication reviews 
show potential in reducing patient’s pharmaceutical care issues in the cancer outpatient setting 
in Finland. 
What remains unknown? 
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It remains unknown whether all cancer patients are adequately managed in respect to their 
pain because our study only included patients already prescribed an opioid. Self-reported 
adherence measures need to be validated to use for reliable assessing of adherence to 
analgesic regimen. The standard measure to assess adherence remains to be determined. There 
is a warrant for a larger study to evaluate pharmacist conducted medication reviews and their 
efficacy. It remains unclear whether pharmacist completed medication reviews are cost 
effective and do they reduce hospital admissions. 
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Appendix 1. Interview form. 
 
Medication reconciliation form    Date: 
____________________  
Patient name: ____________________________Social security number: ___________________________ 
Reason for admission (Eg. triage form): ____________________________________________________ 
Weight: _____kg,   Height: ______cm,   P-Krea: _____________(date),   RR and BPM _______________ 
(date)    
Allergies: ______________________________________________________________________________ 
Changes in diet:_________________________________________________________ 
Smoking: no ___yes ______ cigarettes/day 
Alcohol:     no ___yes ______ doses/week 
Patient’s medication: 
1Prescription (R), OTC (I) 
2Medical history (SK), Medication card (L), Interview (H), Prescriptions (R), Dose dispensing (A), Hospice care 
(HP),  
e-Archives (E), Relative (O),  Other (M)__________________ 
3Regular (S) and per needed (T) 
Drug, strength and 
formulation (R/I1) 
Where was 
the info 
received 
(code2)? 
Dosing 
(eg. 1 tbl x 3) 
Dosing times S/T3 Comments, and if needed the 
indication for the medication 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
List assisting medication reconciliation: Does the patient use: 
medications affecting blood clotting___ medication for heartburn___ medication for constipation___ 
medications for flue___ painkillers___ medicinal cream___ 
antiallergics___ vitamins___ injectable medicine (insulin etc.)___ 
cough medicine___ natural remedies___ eye medication (drops)___ 
1x/week or 1x/month etc. administrated 
medications___ 
medical patches (nicotine, nitro, 
hormone)___ 
aerosols (asthma, nitro etc.) ___  
drugs that belong to someone else ___ 
 
 
 
When was the last time you took your medicines? 
_______________________________________________ 
Has your medication been altered during the last month? No ___ Yes ___, what? 
_______________________________________________________________________________________
_______________________________________________________________________________________
______  
 
Pain management 
 
What is currently the intensity of your pain in scale 0-10? _____ 
Have you noticed fluctuation in the intensity of pain during different times of the day? When is the pain 
worst? ________________________________________________________________________ 
Can you estimate the intensity of pain when it is at its worst in scale 0-10? ___________________ 
What do you suspect to cause the pain fluctuation? ___________________________________________ 
What other methods do you use to manage your pain? _________________________________________ 
At what times do you take your pain medications? 1.____ 2.____ 3.____ 4.____ 5.____ 
Are you satisfied with your pain management? Yes ___ No ___ 
How would you change your pain management? 
_______________________________________________________________________________________
_______________________________________________________________________________________ 
Problems (Fill in the medication list comment section): 
Problems in swallowing ____                       Side effects ____ 
Difficult administration ____                       Fear ____ 
Difficult dispensing (eg. package opening)____                                                                             Forgetfulness ____ 
Missing or unclear instructions ____                       Medication cost ____ 
Inefficacy or excessive efficacy ____                       Other, what? ________________ 
  
Assisting list to detect side effects: 
Heartburn __     Nausea         ___     Dry mouth  ___     Diarrhea             ___     Constipation ___ 
Pain         ___      Sweating      ___     Urinary difficulties   ___  Itching                ___     Amnesia         ___ 
Dizziness  ___    Falls               ___     Shortness of breath___   Chest pain         ___     Arrhythmias  ___ 
Cough       ___    Sedation     ___     Sleep problems      ___    Anxiety              ___     Confusion      ___ 
Swelling ___      Restless legs, cramps, leg pain    ___   Visual disturbances        ___   
Description:_____________________________________________________________________________
_______________________________________________________________________________________
______ 
 
Interviewers comments on the interview etc.  
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________ 
Additional information: 
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________ 
 
Remind the patient to keep medication list updated and with every time the patient uses health care 
services! 
 
Interviewer: _____________________________________ 
 
 
Patient adherence to pain management 
 
Morisky medication adherence scale: 
 
Do you ever forget to take your medicine? Yes ___  No___ 
Are you careless at times about taking your medicine? Yes ___ No ___ 
When you feel better do you sometimes stop taking your medicine? Yes ___ No ___ 
Sometimes if you feel worse when you take the medicine, do you stop taking it?  
Yes ___    No ___ 
 
Have you sometimes altered your medication without discussing it with the physician? Yes ___ No ___ 
Why?__________________________________________________________________________________
___ 
Have you sometimes needed more pain medications than you have been prescribed or is recommended in 
the package leaflet because of intense pain? No ___  Yes____, what medications have you taken more 
_______________________________________________________________________________________ 
Do you use pain medications on regular or as needed basis? 
________________________________________ 
Do you have: 
Concerns of side effects __ Concerns of addiction__ Concerns of tolerance __ 
Too expensive pain medications__ Difficulties in using your pain medicines__ 
Do your pain medications disturb your everyday life?___________________________________  
Do you think your patient-physician relationship is good? Yes __ No __ 
Why?________________________________ 
Have you got enough information regarding to your disease? Yes __ No __ In what do you need more 
information?_______________________ 
Have you got enough information regarding to your pain management? Yes __ No __ In what do you need 
more information?_____________________ 
Is your pain followed up frequently enough? Yes __ No __ What is it a result from?____________________ 
 
Other concerns regarding the pain medications? 
_______________________________________________________________________________________
_______________________________________________________________________________________ 
 
 
  
 
 
Appendix 2. Medication safety check form. 
 
MEDICATION SAFETY CHECK FORM 
Name ______________________ Social security number: ______________________ 
 GFR (CKD-EPI -formula) ________ 
 Cause of hospital admission: 
 Detected side effects: 
 
PROBABLE ASSOCIATION WITH THE MEDICATION: 
1. Side effects: (Duodecim-medication database)   
2. Overlap; medicines and therapeutical groups: 
(eg..Duodecim-medication database, Pharao-database)  
 
3. Interactions; pharmacokinetic and pharmacodynamic: 
(eg.. SFINX-Pharao-database)  
 
 
4. Dose: (Duodecim-medication database and if GFR < 60 
ml/min Renbase-database) 
 
5. Dosing time: (eg. Finnish Medical Journal article: 50–
52, p.3340–42, 2013) 
 
6. Missing medications: (Duodecim-database)  
7. Drugs to avoid in the elderly; ≥ 75-year-old. 
(Medications in the elderly -database)  
 
8. Adherence to medication: (Interview form)  
9. Risk medicines and association with symptoms 
(List for risk medicines) 
 
10. Other important observations: (Eg. 
inappropriateness of initiated drugs with home medication, 
prize, reimbursement, availability, easier dosing technique, 
length of treatment, no indication) 
 
 
 
SUMMARY OF THE OBSERVATIONS FOR THE PHYSICIAN: (On separate sheet of paper) 
1. Problems associated with the cause of admission or symptoms 
2. Other acute recommendations 
3. Observations to take into account in further care 
Date, completed by:  
Summary delivered to physician (date and physician):  
 
